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ABSTRACT 
Advanced, metastatic stages of breast cancer are associated with high morbidity and 
mortality, and there is a need to establish a proof-of-concept for novel compounds 
that can change this scheme. Fibroblast growth factors and their receptors (FGFRs) 
are altered in about 18% of breast cancers, resulting in malignant growth and 
resistance to conventional therapies. During the past few years many compounds 
inhibiting the activity of FGFRs have been discovered but not yet approved for breast 
cancer.  
In this study, the effects of pharmacological inhibition of FGFRs by FGFR-
selective and non-selective inhibitors on proliferation, apoptosis, migration, invasion 
and angiogenesis were evaluated by different in vitro and in vivo models, and in ex 
vivo explant cultures using clinical breast cancer tissue specimens.  
FGFR1 was a major regulator of breast cancer growth. FGFR selective inhibitors 
were most effective in FGFR-amplified cells. FGFR inhibitors decreased 
proliferation of breast cancer cells, which was the major cause of growth inhibition. 
Migration and invasion were also inhibited, and induction of apoptosis was observed 
in certain experimental models. FGFR inhibitors decreased tumor growth in 
subcutaneous models, and also in a model mimicking growth of bone metastases in 
vivo. FGFR inhibitors did not have any harmful effects on healthy bone or on bone-
forming osteoblasts.  
In conclusion, FGFR inhibitors showed many anti-tumor effects in breast cancer. 
Many of these compounds are currently being evaluated in clinical trials. 
KEYWORDS: breast cancer, bone metastasis, fibroblast growth factor receptor, 
drug discovery  
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TIIVISTELMÄ 
Edennyt, etäpesäkkeitä muodostava rintasyöpä lisää merkittävästi kuolleisuutta 
potilaissa, ja uusia tehokkaita lääkkeitä sen hoitamiseen tarvitaan kipeästi. Noin 18 
%:ssa rintasyövistä havaitaan fibroblastikasvutekijöissä ja niiden reseptoreissa 
(fibroblast growth factor receptor, FGFR) geenimuutoksia, jotka johtavat syövän 
kehittymiseen ja lopulta lääkeresistenssiin. Viime vuosina on kehitetty useita 
FGFR:iin vaikuttavia lääkeaineita, mutta niitä ei ole vielä hyväksytty rintasyövän 
hoitoon. 
Tässä tutkimuksessa selvitettiin FGFR-epäselektiivisten sekä FGFR-selektii-
visten pienimolekyylisten inhibiittoreiden vaikutuksia solujen jakautumiseen, 
solukuolemaan, liikkumiseen, tunkeutumiseen ja verisuonten muodostukseen. 
Tutkimuksessa käytettiin erilaisia solu- ja tuumorimalleja, sekä potilaista saatuja 
rintasyövän kudosviljelmiä. 
Tutkimuksessa FGFR1 osoittautui voimakkaaksi rintasyövän säätelijäksi. 
FGFR-selektiiviset inhibiittorit olivat erityisen tehokkaita malleissa, joissa oli FGFR 
geenimuutoksia. FGFR-inhibiittorit hidastivat ensisijaisesti syöpäsolujen jakautu-
mista ja siten syövän kasvua. Lisäksi inhibiittorit vähensivät syöpäsolujen liikku-
mista ja tunkeutumista, sekä lisäsivät solukuolemaa tietyissä tutkimusmalleissa. 
FGFR inhibiittorit vähensivät syövän kasvua myös primäärituumorimallissa, sekä 
mallissa, jossa syöpäsolut kasvoivat luussa, vaikuttamatta kuitenkaan terveeseen 
luuhun tai luuta muodostaviin soluihin. 
Yhteenvetona voidaan todeta, että FGFR inhibiittoreilla on monia syövän kasvua 
estäviä vaikutuksia. Tällä hetkellä näiden inhibittoreiden tehoa arvoidaan kliinisissä 
kokeissa.  
AVAINSANAT: rintasyöpä, luuetäpesäke, fibroblastikasvutekijäreseptori, lääke-
kehitys 
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HIF-1 Hypoxia inducible factor 1 
HSPG Heparan sulfate proteoglycan 
IGF Insulin-like growth factor 
IL Interleukin 
JNK c-Jun N-terminal kinases 
Ki67 Antigen KI-67 
MAPK Mitogen-activated protein kinase 
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MDSC Myeloid –derived suppressor cell 
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MMP Matrix metalloproteinase 
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PTHrP Parathyroid hormone-related peptide 
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P53 Protein 53 
RAF1 RAF proto-oncogene serine/threonine-protein kinase 
RANK Receptor activator of nuclear factor κ B 
RANKL Receptor activator of nuclear factor kappa-Β ligand 
Rb Retinoblastoma protein 
RFS1 Remodeling and spacing factor 1 
RKT Receptor tyrosine kinase 
SEF Similar Expression to FGFs 
SERM Selective estrogen receptor modulator 
Snail Zinc finger protein SNAI1 
SOS1 Son of sevenless homolog 1 
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STAT Signal transducer and activator of transcription 
TACC1 Transforming acidic coiled-coil-containing protein 
TGFβ Transforming growth factor beta 
TK  Tyrosine kinase 
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1 Introduction 
Breast cancer is the most common cancer in women, counting approximately 30% 
of all cancers. In Finland, 4742 new breast cancer diagnoses were made during the 
years 2012-2016 according to Nordic Cancer Registry. Majority of the diagnoses are 
made when the cancer is so called primary breast cancer, affecting only the breast 
where the malignant growth is originating. Primary breast cancer can be sufficiently 
treated, and the 1-year and 5-year survival rates are relatively good.  One year after 
the diagnosis about 97%, and after 5 years about 90% of the patients are alive.  
However, this situation dramatically changes when the disease relapses and 
metastases, tumor cells originating from the breast that are growing in distant sites 
of the body, are observed. In breast cancer, the majority of metastases are formed to 
skeleton. Bone metastases are difficult to treat and they decrease the 5-year survival 
to 27%. Development of targeted therapies has improved the situation, but bone 
metastases are still described as incurable. Therefore, novel treatments that can also 
inhibit tumor growth at metastatic locations are urgently needed. 
In this thesis, breast cancer and bone metastases with respect to current treatment 
options are discussed. This thesis evaluates the role of fibroblast growth factor 
receptors (FGFRs) in the regulation of breast cancer growth in both in vitro cell 
culture models and in vivo tumor models. The effects of investigational FGFR 
inhibitors were evaluated in in vitro cell culture models, in vivo primary and bone 
metastasis models, and ex vivo human breast cancer tissue explant cultures to 
demonstrate if they would provide a potential treatment option also for advanced 
breast cancer.
 2 Review of the Literature 
2.1 Breast cancer 
2.1.1 Subtypes and molecular characteristics 
Breast cancer consists of several subtypes depending on the origin of malignant 
growth and molecular characteristics of the tumor. Based on tumor origin, breast 
cancers can be divided into two main categories of ductal (75 – 80 %) and lobular 
(10 – 15 %) carcinomas. Ductal carcinomas originate from the breast ducts and 
lobular carcinomas from the breast lobules. Other subtypes are tubular (Limaiem et 
al., 2019), medullary (Romaniuk et al., 2015) and mucinous carcinomas (Lei et al., 
2016), but these types are more uncommon and have distinctive clinical features 
(Huovinen 2013, Dieci et al., 2014). 
Characterization of breast cancer is based on so called TNM staging system, 
which was first published in 1959 and thereafter renewed several times (Sawaki et 
al., 2018). In this staging system ‘T’ refers to tumor size, ‘N’ the number of lymph 
nodes with tumorous growth, and ‘M’ the number of observed metastases (Sawaki 
et al., 2018, Jung et al., 2015). The staging system is used to predict prognosis and 
assist in treatment planning (Sawaki et al., 2018, Jung et al., 2015, Yoon et al., 2019). 
In the past few years this staging system was updated to include “I” indicating 
immunological scoring, which evaluates immune cell infiltration into the tumor 
(Galon et al., 2014, Galon et al., 2012) and is used as a basis for treating patients 
with immunogenic tumors with immunomodulators (Criscitiello et al., 2015). 
Current classification of breast cancer to several subgroups is based on different 
pathological features, clinical outcome, and expression of well-known molecular 
markers (Dai et al., 2015, Prat et al., 2015). These markers include tumor histological 
grade, proliferation rate, and estrogen receptor (ER), progesterone receptor (PR) and 
human epidermal growth factor receptor 2 (HER2/neu/erbB2) status (Yersal 2014, 
Dai et al., 2015, Yoon et al., 2019, Robertson et al., 2018). Current breast cancer 
subtypes are summarized in Table 1 below. 
Tiina Kähkönen 
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Table 1.  Summary of breast cancer subtypes, molecular markers, histological and 
proliferation rate, and predicted outcome.  
Tumor 
type 
Sub-
type 
Molecular profile Histo-
logical 
grade 
Prolife-
ration 
rate 
Predicted 
outcome 
Location of 
metastases 
Luminal A ER+ PR+ HER2- low low good skeleton 
B ER+ PR+ HER- high high medium skeleton 
HER2+  ER- PR- HER+ high high poor brain and soft 
tissues 
Basal, 
TNBC 
 ER- PR- HER2- high high poor lungs and 
skeleton 
Normal  ER+ PR+ HER2- low low medium - 
Abbreviations: ER = estrogen receptor, PR = progesterone receptor, HER2 = human epidermal 
growth factor receptor 2, TNBC = triple-negative breast cancer. The table is based on the following 
publications: Huovinen 2013, Dieci, et al., 2014. 
Luminal-type breast cancers are the most common, counting about 75% of breast 
tumors (Yersal et al., 2014, Turner 2008b, Li et al., 2015). They are ER positive and 
express many luminal cell markers such as cytokeratines (Yersal 2014, Dai et al., 
2015). These tumors can further be divided into two subgroups of A and B. Luminal 
A breast tumors are most common and count over 50% of all breast cancers (Yersal 
et al., 2014, Dai et al., 2015, Li et al., 2015). They usually have low histological 
grade and patients with these tumors have good prognosis (Yersal et al., 2014, Dai 
et al., 2015, Li et al., 2015). Relapse rate is low and metastases are most commonly 
observed in the skeleton (Yersal et al., 2014). Fifty to twenty percent of breast 
cancers are of luminal B tumors (Ades et al., 2014, Li et al., 2015). They are usually 
more aggressive than luminal A tumors and have higher histological grades and 
proliferation rates (Yersal et al., 2014, Dai et al., 2015, Ades et al., 2014). Also, the 
relapse rates are higher and survival rates lower (Yersal et al., 2014, Dai et al., 2015, 
Ades et al., 2014). The main difference between the luminal A and B tumors is the 
higher proliferation rate in A tumors, which can be explained by upregulation of 
proliferation associated genes (Yersal 2014, Dai et al., 2015, Ades et al., 2014).  
Fifty to twenty percent of breast cancers are HER2 positive (Asif et al., 2016). 
HER2 positivity correlates with high proliferation rate, aggressive disease and poor 
clinical outcome (Yersal et al., 2014, Li et al., 2015, Asif et al., 2016). This may be 
partly due to mutation in the tumor suppressor p53, which occurs in about 40% of 
HER2 positive tumors. HER2 positivity is also linked to genes controlling invasion 
and metastasis (Yersal et al 2014, Dai et al., 2015). Metastases of this tumor type are 
usually formed to brain or soft tissues (Yersal et al., 2014).  
Review of the Literature 
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Depending on the cohort, 8 – 37% of breast cancers are basal type (Yersal et al., 
2014, Li et al., 2015, Prat et al., 2015, Lee et al., 2018). Basal-type breast cancers 
are ER, PR and HER2 negative and are often referred as triple-negative breast cancer 
(TNBC). These tumors have frequently mutation in p53 and retinoblastoma (Rb) 
pathways (Yersal et al., 2014). TNBC is an aggressive subtype of tumors with poor 
prognosis and high incidence of metastasis to skeleton and lungs (Yersal et al., 2014, 
Dai et al., 2015, Tseng et al., 2013).  
Normal-type breast cancers count 5 – 10% of breast tumors, and the predicted 
outcome in patients is relatively good (Yersal et al 2014, Prat et al., 2015, Russnes 
et al., 2017). The tumors express a large number of adipose tissue -related genes and 
are somewhere in between luminal A and B tumors (Yersal et al., 2014, Russnes et 
al., 2017).  
Even though tumor characterization is well established and widely used, it may 
be inefficient in some cases. This is because the characterization does not always 
provide enough information for personalized medicine as many histologically 
similar tumors may behave differently (Yersal et al., 2014, Badve et al., 2015). This 
problem is a result of tumor heterogeneity caused by variation in marker expressions 
both inter- and intratumorally (Song et al., 2016), and especially in metastases 
growing in different locations of the body (Yang et al., 2017, Roulot et al., 2016, 
Ellsworth et al., 2017). New biomarkers such as microRNAs (McGuire et al., 2015, 
Bertoli et al., 2015), extracellular vesicles (Sadovska et al., 2015), circulating tumor 
DNAs (ctDNA) (De Mattos-Arruda et al., 2016, Wang et al., 2017), and epigenetic 
modulators (Basse et al., 2015) are under investigation to be used for identifying 
patients that are likely to respond to certain treatments (Dai et al., 2015, Roulot et 
al., 2016). 
2.1.2 Metastatic process 
Recurrence of breast cancer can occur in three ways: local recurrence of the 
previously operated breast, in the other breast, or formation of metastases. 
Metastases are tumors that are growing in a location of the body that is not directly 
linked to the primary tumor (Lehti et al., 2012, Eccles et al., 2013, Scully et al., 
2012). The word metastasis comes from the Latin and means ‘to change place’. The 
site for metastasis formation can in some cases be explained by the anatomical 
location and the vasculature near the primary tumor. For example, in the case of 
breast cancer through vena cava superior the cells have an easy access to lungs. 
However, this is not true for all tumors, and many tumors have a distinct pattern of 
metastasis formation. This was observed by Paget in 1889 when he came up with the 
well acknowledged seed-and-soil –theory (Eccles et al., 2013). According to Paget’s 
theory, all seeds (cancer cells) need sufficient and favorable growing conditions 
Tiina Kähkönen 
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(soil) to form metastases (Kozlowski et al., 2015, Lorusso et al., 2012). Also, breast 
cancer has its favorite ‘soils’ that are bone, lungs, liver, abdominal cavity with its 
lymph nodes, and brain (Huovinen 2013, Eccles et al., 2013). This cell seeding to 
certain tissue microenvironments was later confirmed by the expression of 
chemokines or other molecular markers in the tumor cells and in the cells of the 
metastatic microenvironment. For example, HER2 expressing tumors metastasize to 
brain where its ligands heregulin and neuregulins are highly expressed, and tumors 
expressing the chemokine receptor CXCR2 metastasize to lungs where its ligand 
CXCL12 is highly expressed (Kozlowski et al., 2015). Additionally, osteoblast 
precursor cells secrete CXCL12, and the interactions between CXCL12 and CXCR4 
contribute to formation of bone metastases (Devignes et al., 2018). Overall, bone is 
the most preferred site of metastasis in breast cancer, counting about 70 – 80% of all 
breast cancer metastases. Bone metastases are discussed separately in chapter 2.1.3. 
The metastatic process can be divided into several critical steps that the tumor 
cells need in order to develop clinically detectable metastases. These steps are: a) 
angiogenesis – and lymphangiogenesis; b) intravasation into the circulation; c) 
survival in the circulation; d) extravasation to the new tissue microenvironment; e) 
modulation of metastatic microenvironment to enable tumor growth, and; f) 
metastatic growth and tumor-induced changes in the metastatic microenvironment 
(Lehti et al., 2012, Scully et al., 2012). These steps are discussed in more detail in 
the following paragraphs.  
 
a. Angiogenesis – and lymphangiogenesis 
Tumors that are over 2 cm in diameter have a higher recurrence rate, and the 
possibility of micrometatasis already at diagnosis is greater. This can be explained 
by the increasing need for nutrients in the growing tumor (Scully et al., 2012). The 
tumor growth makes the tumor microenvironment hypoxic, leading to production of 
angiogenic factors (Bielenberg et al., 2015). Tumor secreted angiogenic factors 
include for example hypoxia inducible factor 1 (HIF-1), vascular endothelial growth 
factor (VEGF) and fibroblast growth factor (FGF) that can recruit endothelial cells 
to migrate towards the tumor (Bielenberg et al., 2015, Scully et al., 2012). The 
endothelial cells secrete many enzymes that help them to migrate towards the tumor, 
and the migrated endothelial cells finally form a lumen to allow blood flow in the 
newly formed vessels (Bielenberg et al., 2015). The larger the tumor grows the more 
nutrients it needs, which then increases blood vessel formation and the chance of 
cancer cells to escape from the primary tumor (Bielenberg et al., 2015).  
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b. Intravasation in the circulation 
Intravasation is the process where cancer cells detach from surrounding tumor cells 
and break the basement membrane to enter the blood vessels (Bielenberg et al., 
2015). This process requires the cancer cells of epithelial origin to obtain 
mesenchymal cell phenotype, and this process is called epithelial-to-mesenchymal 
transition (EMT) (Bong et al., 2017). EMT is mediated by many factors including 
tumor necrosis factor alpha (TNFα), insulin-like growth factor (IGF) and epidermal 
growth factor (EGF) (Khalid et al., 2015, Bong et al., 2017, Tan et al., 2015). In the 
process, cancer cells acquire mesenchymal cell properties to be able to migrate, 
invade and survive in vasculature (Khalid et al., 2015). Migration and invasion of 
cancer cells is regulated by loss of E-cadherin and increased expression of N-
cadherin, which regulate cell-cell junctions in epithelial and stromal cells, 
respectively (Scully et al., 2012). This change in expression also results in 
morphological changes towards spindle-like cells that are able to invade through the 
basal membrane (Bong et al., 2017). Adherence of tumor cells to extracellular matrix 
is mediated by integrins, and later increased production of matrix metalloproteinases 
(MMPs) helps the cells to break the basal membrane (Scully et al., 2012). This 
process can also be enhanced by stromal cells. For example, a decrease in fibroblast-
produced CXCL12 increases vascular permeability by decreasing endothelial cell 
junctions (Ahirwar et al., 2018). When the cancer cells enter the circulation, they are 
called circulating tumor cells (CTCs) (Bidard et al., 2016). In patients, CTCs are 
detected in circulation very early in the disease, and they are a prognostic factor both 
in early stage and metastatic breast cancer in predicting metastasis occurrence and 
their response to therapies, respectively (Bidard et al., 2016). 
 
c. Survival in the circulation 
Cancer cell survival in the vasculature is a crucial characteristic for metastasis 
formation (Scully et al., 2012, Kozlowski et al., 2015). Blood circulation is a hostile 
environment for CTCs and majority of them die shortly after intravasation 
(Bielenberg et al., 2015, Cominetti et al., 2019). The mechanism of cancer cell 
survival in vasculature is not well understood. The CTCs can undergo apoptosis due 
to high pressure that they encounter, and one suggested mechanism for surviving the 
pressure is increased release of ATP from mechanosensitive pannexin-1 (PANX1) 
channels that disables the cells to undergo apoptosis (Furlow et al., 2015). CTCs are 
also actively killed by natural killer (NK) cells (Bielenberg et al., 2015, Cominetti et 
al., 2019), but they are to some extent protected by platelets (Bielenberg et al., 2015). 
Also, the survival is enhanced when the CTCs stick together as aggregates or form 
aggregates for example with lymphocytes (Lehti et al., 2012, Kozlowski et al., 2015). 
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The bigger the glum is, the more likely it is to stuck in the capillary, allowing the 
CTCs to access the stroma. 
 
d. Extravasation to the new tissue microenvironment 
Extravasation is the process where the CTCs enter the stroma. Extravasation occurs 
through endothelial wall by loosening endothelial cell junctions (Lehti et al., 2012, 
Scully et al., 2012, Bielenberg et al., 2015).  Then the tumor cells need their invasive 
properties and proteolytic enzymes to alter their surroundings to support the growth 
of metastasis in the new tissue microenvironment (Lehti et al., 2012, Scully et al., 
2012). Mediators of extravasation are not completely understood. Some studies 
indicate that for example cysteine rich angiogenic inducer 61 (CYR61) is associated 
with aggressive disease and silencing of the gene blocks extravasation of TNBC cells 
(Huang et al., 2017). Another factor observed to inhibit invasion and extravasation, 
but not proliferation and growth, is transient receptor potential vanilloid subtype 4 
(TRV4) (Lee et al., 2016).  
 
e. Modulation of metastatic microenvironment to enable tumor growth 
After extravasation, the cells are called disseminated tumor cells (DTCs). In patients, 
the number of DTCs alone is not a prognostic factor for distant recurrence free 
survival, but when combined with the number of CTCs it provides a prognostic 
factor for overall survival (Magbanua et al., 2019). Once disseminated, the tumor 
cells encounter another hostile microenvironment and in order to grow they need to 
adopt to this new microenvironment. In fact, many DTCs enter apoptosis or are 
eliminated by immune cells (Bielenberg et al., 2015). To prevent this, DTCs can 
enter a dormant, non-proliferative state where they are protected from elimination 
by apoptosis and are also resistant to many therapies (Bielenberg et al., 2015). Many 
factors such as F-box/WD repeat-containing protein 7 (Fbxw7) and IL-6 cytokine 
leukemia inhibitory factor (LIF) can keep tumor cells dormant (Shimizu et al., 2019, 
Johnson et al., 2016). Deletion of Fbxw7 forces DTCs to proliferate and sensitizes 
them to chemotherapy (Shimizu et al., 2019). For growth, tumor cells need their 
epithelial cell properties again, and for that they undergo a reverse process called 
mesenchymal-to-epithelial transition (MET) (Cominetti et al., 2019). This process 
then allows tumor cells to proliferate and to form secondary tumors (Cominetti et al., 
2019).  
 
The last step of growth of metastases and tumor-induced changes in the metastatic 
microenvironment are discussed in the next chapter in the concept of bone 
metastasis. 
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2.1.3 Bone metastases 
Skeleton is the most common site for metastasis in breast cancer (Rose et al., 2006, 
Sowder et al., 2019, Wang et al., 2017). Bone metastases are most commonly formed 
to spine, ribs, pelvis, proximal femur, and also to the skull (Weidle et al., 2016, Rose 
et al., 2006). At physiological state, bone turnover is regulated by the activity of bone 
forming osteoblasts and bone resorbing osteoclasts. Osteoblasts are differentiated 
from mesenchymal stromal cells (MSCs) and their differentiation is regulated by 
many factors that are also active in cancer such as FGF/FGFR pathway (Marie et al., 
2012). Osteoclasts are differentiated from hematopoietic stem cells (HSCs), and 
increased number and activity of osteoclasts causes osteolytic bone changes in breast 
cancer that are described later in this chapter (Johnson et al., 2019). 
Bone microenvironment is in many ways a unique and favorable soil for 
metastasis. Once the CTCs arrive to bone they occupy the hematopoietic stem cell 
niches that support DTCs, and in these niches the cells can stay dormant from months 
to decades (Sowder et al., 2019, Weidle et al., 2016). The reason for the long 
dormancy is not fully known but long adaptation to the new microenvironment has 
been suggested (Weidle et al., 2016, Neves-E-Castro 2006).  The reasons why tumor 
cells favor bone microenvironment may be related to interactions of tumor cells with 
bone-derived cells such as hematopoietic and mesenchymal stem cells, endothelial 
cells, bone-forming osteoblasts and bone-resorbing osteoclasts, and bone marrow 
adipocytes that are present during the metastatic process (Sowder et al., 2019, 
Rossnagl et al., 2018). Furthermore, bone is a fertile microenvironment for tumor to 
grow as it contains many growth factors and cytokines (Sowder et al., 2019). Bone 
marrow is also a hypoxic microenvironment (Sowder et al., 2019), and hypoxia is 
known to regulate tumor growth, migration, invasion, formation of metastases, 
tumor dormancy in bone, and also resistance to therapies (Butturini et al., 2019), but 
also pathways that regulate bone resorption and formation such as the receptor 
activator of nuclear factor kappa-Β (RANK)/RANK ligand (RANKL) -pathway 
(Gilkes 2016).  
In breast cancer, bone metastases are usually classified as osteolytic where the 
bone is degraded faster than new bone is formed, resulting in pathological bone loss 
(Weidle et al., 2016, Rose 2006). In some cases also osteosclerotic lesions with 
increased bone mass are observed (Weidle et al., 2016, Makhoul et al., 2016). 
Usually bone metastases are mixed, including both types of lesions in the same 
patient, but the metastases are classified based on the dominant process. 
Development of osteolytic metastases is a consequence of increased number and/or 
activity of osteoclasts. This happens through tumor cells acting in bone to modulate 
the microenvironment to support their growth (Rucci et al., 2018). First factors 
characterized in this process were parathyroid hormone-related peptide (PTHrP) 
(Guise et al., 2002) and TGFβ, which can modulate PTHrP secretion (Yin et al., 
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1999). PTHrP increases the expression of RANKL in osteoblasts, which then binds 
to its receptor RANK in osteoclasts, leading to increased bone resorption (Rucci et 
al., 2018). Osteoblasts also secrete other factors such as IL-6 and TNFα that increase 
the differentiation and activity of osteoclasts (Rucci, et al., 2018). Also, breast cancer 
cells inhibit osteoblast differentiation through RUNX2 mediated pathways and 
increase expression of sclerostin, which further contributes to osteolytic phenotype 
(Mendoza-Villanueva et al., 2011). When osteoclasts degrade bone, many growth 
factors such as TGFβ, FGFs, IGFs and PDGF are released from bone matrix and 
further promote tumor growth in bone metastases (Rucci et al., 2018). Tumor cells 
can also promote differentiation of osteoclast precursor cells directly (Rucci et al., 
2018). This well described phenomenon is called the vicious cycle of bone metastasis 
(Weidle et al., 2016, Makhoul et al., 2016, Johnson et al., 2018, Guise et al., 1996). 
Additionally, immune cells can contribute to tumor growth in bone in the vicious 
cycle (Owen et al., 2019). Breast cancer cells also express so called osteolytic drivers 
that increase cancer-induced bone degradation (Johnson et al., 2018, Brook et al., 
2018), including for example the transcription factor zinc finger protein GLI2 
(GLI2), connective tissue growth factor (CTGF) (Johnson et al., 2017), the cytokine 
IL-11 (Liang, Ma et al., 2019), and many more (Awolaran et al., 2016). Clinically, 
problems especially in osteolytic bone metastases include bone-related pain and 
fractures, hypercalcemia and spinal cord and nerve compression, which decrease the 
quality of life of the patients (Weidle et al., 2016).  
2.2 Breast cancer treatment 
Primary care for breast cancer is surgery (Turner et al., 2008a, Kumar et al., 2013). 
When possible, parts of breast can be saved in so called conserving surgery (Turner 
et al., 2008a) that is accompanied by post-operative radiation or chemotherapy, 
and/or hormonal or HER2 targeting treatments when applicable (Turner et al., 
2008b). For example, post-operative radiation can reduce the risk for local 
recurrence by about 20% (Turner et al., 2008a).  Also, post-operative chemotherapy 
should be given early to improve the survival of patients with aggressive tumor 
subtypes (Yu et al., 2017). In some cases radiation or cytotoxic treatment can also 
be applied in a neoadjuvant setting prior to surgery (Eccles et al., 2013), which 
decreases tumor volume and helps surgical removal of the tumor (Al-Hilli et al., 
2016). There is no direct consensus about the best timing for surgery after 
neoadjuvant chemotherapy (Al-Hilli et al., 2016). All surgeries are accompanied 
with sentinel lymph node examination to identify metastases in the lymph nodes 
(Kumar et al., 2013). If found positive, axillary lymph node dissection is performed, 
but whether this improves the survival is still questionable (de Boniface et al., 2017). 
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Radiation therapy was first tried on breast cancer patients in the 1930s with 
promising results (Akram et al., 2012). After that, radiation therapy has evolved and 
currently it is applied as a 3D Conformal Radiotherapy (3DCRT) where the radiation 
is directed to the tumor, minimizing the exposure to healthy tissue (Akram et al., 
2012).  
Chemotherapy is a possibility for treatment of several breast cancer types. The 
anthracyclines doxorubicin or epirubicin were the first treatment options started in 
the 1980s that decreased breast cancer mortality by 20 – 38% (Turner et al., 2008b, 
Greene et al., 2015). Later anthracyclines were combined with the taxanes docetaxel 
or paclitaxel, and the combinations further reduced mortality by 15% (Turner et al., 
2008b, Sparano 2000, Saloustros et al., 2008). Docetaxel has become a standard 
therapy for patients who have failed while on anthracycline therapy (Nabholtz et al., 
2005). However, not all women benefit from chemotherapy, and the current 
challenge is how to identify the responders (Turner et al., 2008b). Currently, 
Oncictype DM, MammaPrint and H/I tests are used to predict the responses to 
chemotherapy (Turner et al., 2008b), and further personalized medicine approached 
using gene expression profiles are being developed (Yu et al., 2017). 
Hormonal therapies are applied for patients with hormone receptor positive 
breast cancer. There are two classes of hormonal therapies, anti-hormonal therapy 
(tamoxifen or fulvestrant) and aromatase inhibitors (letrozole, anastozol, or 
exemestan). Anti-hormonal therapies block the estrogen receptor and estrogen 
mediated actions (Turner et al., 2008b). Aromatase inhibitors block the actions of an 
aromatase enzyme that converts androgens to estrogens (Turner et al., 2008b). The 
decision of which hormonal therapy the patients receive is based on the age of the 
patient. Premenopausal women typically receive tamoxifen as single agent or 
combined with chemotherapy, and postmenopausal women receive aromatase 
inhibitors (Turner et al., 2008b, Draganescu et al., 2017). Tamoxifen reduces the risk 
of cancer recurrence by 40% and mortality by 30% (Turner et al., 2008b, Draganescu 
et al., 2017). In postmenopausal women aromatase inhibitors are superior compared 
to tamoxifen, increasing disease-free survival by 13 – 40% (Turner et al., 2008b). A 
meta-analysis comparing the effects of tamoxifen and aromatase inhibitors showed 
that aromatase inhibitors were more effective in preventing relapses in the first 4 
years of follow-up, and mortality was also lower during a 10 year follow-up time 
(Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2015). However, the 
individual variation in response to aromatase inhibitors has been a problem, and 
CYP19A1 polymorphism and mutations in ESR1 have been suggested to predict the 
responses (Hamadeh et al., 2018).  
Patients with HER2 overexpressing tumors can be treated with HER2 targeting 
therapies (trastuzumab or lapatinib) (Figueroa-Magalhaes et al., 2014). Trastuzumab 
treatment reduces the risk of relapse by 35 – 52% (Turner et al., 2008b). Trastuzumab 
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can be used as a first-line treatment as monotherapy or combined with antracyclines 
(Figueroa-Magalhaes et al., 2014). Also, the new generation HER2/HER3 antibody 
pertuzumab can be used especially on patients who have relapsed on trastuzumab 
treatment (Figueroa-Magalhaes et al., 2014).   
Treatment of breast cancer will be decided individually, but the treatment plan 
is based on the tumor subtype. Luminal A and B tumors can be treated with hormonal 
therapy because they express ER and PR and are less sensitive to chemotherapy 
(Turner et al., 2008b, Diessner et al., 2016, Dai et al., 2015). In fact, survival of 
luminal A breast cancer patients was not increased when treated with combination 
of hormonal and chemotherapy (Diessner et al., 2016). Luminal B and HER2 
overexpressing breast tumors can be treated with HER2 targeted therapies, and with 
hormonal therapy (Turner et al., 2008b). However, luminal B tumors have lower 
expression of ER and PR and therefore may not respond to hormonal therapies 
similarly than luminal A tumors (Ades et al., 2014). These tumors are also sensitive 
to chemotherapy (Turner et al., 2008b), and combination treatment of hormonal 
therapy and chemotherapy is beneficial (Dai et al., 2015). Some data suggests that 
treatment with the vascular endothelial growth factor A (VEGF-A) antibody 
bevacizumab or the mTOR-inhibitor everolimus could be also beneficial for patients 
with luminal breast cancers (Dai et al., 2015). Additonally, everolimus can overcome 
the resistance to hormonal therapies (Draganescu et al., 2017). HER2 positive 
cancers are treated with HER2 targeting therapies combined with chemotherapy 
(Figueroa-Magalhaes et al., 2014). TNBCs are sensitive to chemotherapy but not to 
hormonal or other targeted therapies (Turner et al., 2008b). In fact, TNBCs are 
aggressive and difficult to treat (Jhan et al., 2017, Yao et al., 2017). New treatment 
options for TNBC are under development, including AR targeting compounds, 
PARP1, mTOR, SRC, vascular epithelial growth factor receptor (VEGFR), FGFR 
inhibitors, and many more (Lee et al., 2018, Yao et al., 2017, Jhan et al., 2017). 
Immunotherapies, agents that activate the patient’s own immune system to fight 
cancer, are also widely studied in different breast cancer subtypes (Nathan et al., 
2018). 
2.2.1 Treatment of bone metastases 
Bone metastases are a vast clinical problem. Over 30% of breast cancer patients are 
in a risk of recurrence, which is typically observed as development of metastatic 
disease (Gluck 2007). There is no complete cure for metastatic cancer, but the 
increase in progression-free survival can prolong the time for development of 
metastases (Gluck 2007, Shen et al., 2017). 
If the patient has received a good response to primary tumor treatment, the same 
treatment can be continued with metastases. Surgery is mainly palliative but some 
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studies also indicate a survival benefit of surgery in metastatic breast cancer 
(Teshome 2018). Radiation therapy can be directed to tumors growing in metastatic 
locations, including bone, where surgery is not an option (Akram et al., 2012). When 
appropriate, hormonal and HER2 targeting agents are widely used in metastatic 
patients. A single agent chemotherapy is usually enough to provide control over 
metastasis growth, but in many cases multiple chemotherapeutics are combined, 
which may lead to over-treatment and higher incidence of adverse effects (Senkus et 
al., 2017). An important aspect in treatment of bone metastases includes treatment 
of cancer-induced bone pain and skeletal health (Gnant et al., 2010). Also, therapies 
with anti-metastatic properties are being developed (Anderson et al., 2019).  
Besides tumor-targeting agents, bone metastases are treated with bone-targeting 
agents that decrease tumor-induced changes in bone (Salmen et al., 2015, Holen et 
al., 2010). In breast cancer, these changes are mainly osteolytic and the bone targeted 
therapies are used to prevent cancer-induced bone loss (Salmen et al., 2015, Luftner 
et al., 2018). Bisphosphonates are a class of compounds that inhibit osteoclasts and 
induce their apoptosis, preventing bone loss (Weidle et al., 2016, Makhoul et al., 
2016). Bisphosphonates can be divided into two groups: non-nitrogen-containing 
(eg. clodronate) and nitrogen containing (eg. zoledronic acid) (Weidle et al., 2016). 
Non-nitrogen containing bisphosphonates are converted to ATP analogs that 
accumulate in osteoclasts, while nitrogen containing bisphosphonates affect the 
mevalonate pathway and prevent Ras, Rho and Rab signaling in osteoclasts (Weidle 
et al., 2016). In general, bisphosphonates delay the occurrence of skeletal-related 
events, such as fractures, in breast cancer patients (Weidle et al., 2016, Salmen et al., 
2015). In fact, bisphosphonates are associated with a decreased risk for developing 
bone metastases, but they have no effect on disease-free survival (O'Carrigan et al., 
2017). Furthermore, they increase the time to first skeletal related event. Some 
differences in response to zoledronic acid have been observed in preclinical pre- and 
postmenopausal bone metastasis models (Ottewell et al., 2014). In the 
postmenopausal model, a higher incidence of bone metastasis was observed, and 
tumor growth was prevented by zoledronic acid, while it had no effect in the 
premenopausal model. Adjuvant bisphosphonate treatment is currently 
recommended for postmenopausal women with high risk of developing bone 
metastases (Hadji et al., 2016).  
Denosumab is a fully humanized monoclonal antibody that binds to RANKL, 
preventing activation of osteoclasts (Weidle et al., 2016). Denosumab is effective in 
preventing skeletal effects in patients with bone metastases (Weidle et al., 2016). 
Denosumab delays the time to occurrence of first skeletal related event over 
zoledronic acid by 22% (Stopeck et al., 2010, O'Carrigan et al., 2017), and increases 
the quality of life of the patients (Martin et al., 2012).  
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Some cancer therapies have harmful effects on the skeleton. This is referred to 
as cancer treatment-induced bone loss (CTIBL) (D'Oronzo et al., 2015). This 
syndrome is caused by many treatments such as hormonal therapies, chemotherapies, 
and some tyrosine kinase inhibitors (D'Oronzo et al., 2015). It is also a well 
acknowledged problem with aromatase inhibitors and has led to their combination 
with anti-resorptive compounds such as denosumab (Makhoul et al., 2016, Abdel-
Rahman 2016). 
2.3 Fibroblast growth factor receptors 
2.3.1 FGFR family 
FGFs and FGFRs are important for many biological functions. They regulate 
embryo- and morphogenesis, homeostasis, wound healing, angiogenesis, and in 
cancer proliferation, survival, differentiation, migration, invasion and apoptosis 
(Beenken et al., 2009, Ornitz et al., 2015a, Turner et al., 2010, Perez-Garcia et al., 
2018, Andre, Cortes 2015, Ornitz et al., 2015b). 
There are altogether 18 FGFs, FGF1-10 and FGF16-23 (Perez-Garcia et al., 
2018). FGFs are further divided to subfamilies of FGF1 (including FGF1 and FGF2), 
FGF4 (FGF4 – FGF6), FGF7, (FGF3, FGF7, FGF10, and FGF22), FGF9 (FGF9, 
FGF16, and FGF22), FGF8 (FGF8, FGF17, and FGF18), FGF15/19 (FGF15/19, 
FGF21, and FGF23), and FGF11 (FGF11 – FGF14) (Porta et al., 2017). The 
classification to subfamilies is based on sequence similarity and biological function 
(Ornitz et al., 2015b). FGF1, FGF4, FGF7, FGF8 and FGF9 family members are 
canonical or paracrine, FGF11 family members are intracellular, and FGF15/19 
family members are endocrine FGFs (Ornitz et al., 2015b, Porta et al., 2017).  
Canonical FGFs bind to heparan sulfate proteoglycan (HSPG) (Beenken et al., 
2009, Ornitz et al., 2015a, Turner et al., 2010, Perez-Garcia et al., 2018, Ornitz et al., 
2015b). HSPGs binds to both the ligand and the receptor, and stabilize the ligand-
receptor -complex by binding to the cell membrane (Beenken et al., 2009, Turner et 
al., 2010, Wesche et al., 2011). HSPG also stabilizes FGFs by binding the ligands 
and thus avoiding their degradation (Beenken et al., 2009, Turner et al., 2010). 
Additionally, FGFs can be bound to FGF- binding proteins (FGFBP) where they are 
stored in inactive state before released and delivered to HSPG (Beenken et al., 2009, 
Ornitz et al., 2015b). Endocrine FGFs bind to α- or β-Klotho and intracellular FGFs 
interact via voltage gated sodium channels (Porta et al., 2017, Ornitz et al., 2015b).  
FGFR family is composed of four receptor tyrosine kinases (FGFR1-4) that are 
encoded by four different genes (Andre et al., 2015, Beenken et al., 2009, Ornitz et 
al., 2015a, Turner et al., 2010, Ornitz et al., 2015b). Additionally, there is a fifth 
FGFR, FGFR like 1 (FGFRL1, or FGFR5) that has structural similarities with other 
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FGFRs but lacks the intracellular tyrosine kinase (TK) domain (Perez-Garcia et al., 
2018, Turner et al., 2010, Ornitz et al., 2015a). Due to alternative splicing, FGFR1-
3 are present in two variants (FGFRIIIb and –c isoforms) (Beenken et al., 2009, 
Ornitz et al., 2015b). In general, b isoforms are expressed in epithelial cells and c 
isoforms in mesenchymal cells (Beenken et al., 2009, Ornitz et al., 2015b). FGFs are 
produced in epithelial or mesenchymal cells and can activate the receptor in the 
opposing cells (epithelial to mesenchymal signaling or vice versa) (Beenken et al., 
2009, Ornitz et al., 2015b). There are some exceptions to this as some FGFs, for 
example FGF1, can bind to both isoforms of the FGFRs (Beenken et al., 2009). 
FGFRs compose of an extracellular domain, a ligand-binding domain, a 
transmembrane domain and an intracellular domain that mediates the downstream 
effects of FGFR activation (Andre et al., 2015, Perez-Garcia et al., 2018). FGFs bind 
to an immunoglobulin (Ig)-like part of the extracellular domain. There are three Ig-
like parts (IgI, IgII or IgIII, named also D1-D3) in FGFRs, and an acid box between 
the IgI and IgII that is important for receptor autoinhibition (Perez-Garcia et al., 
2018, Beenken et al., 2009). IgII and IgIII are the sites for FGF ligand binding 
(Perez-Garcia et al., 2018). Upon binding of the ligand, APT in the ligand binding 
domain is replaced by a higher binging affinity FGF, which then causes the two 
FGFRs to dimerize, and this allows the two TK domains to be in a close proximity 
for transphosphorylation (Ornitz et al., 2015a, Perez-Garcia et al., 2018). After 
transphosphorylation of the TK domains, two main intracellular signaling proteins 
FGFR substrate 2 (FRS2) and phospholipase C (PLC or FRS1) are activated 
(Beenken et al., 2009, Ornitz et al., 2015a, Turner et al., 2010). FRS2 activation 
promotes downstream signaling through RAS–mitogen-activated protein kinase 
(MAPK) or phosphoinositide 3-kinase (PI3K)–AKT pathways that regulate cell 
proliferation, differentiation and survival (Beenken, Mohammadi 2009, Turner, N., 
Grose 2010, Perez-Garcia, Munoz-Couselo et al., 2018). These pathways lead to 
activation of a further pathway including for example JNK and p38 (Ornitz et al., 
2015a). Activation of PLCγ releases calcium ions from the intracellular compartment 
and thus activates calcium-dependent signaling, affecting cell motility (Perez-Garcia 
et al., 2018). FGFRs also mediate gene expression by activating Signal Transducers 
and Activators of Transcription (STAT) pathway, mainly STAT1, -3 and -5, via 
PLCγ pathway (Ornitz et al., 2015a).  
FGFR signaling can be inhibited by sprout-family members (Beenken et al., 
2009, Ornitz et al., 2015a, Turner et al., 2010). This inhibition happens indirectly by 
altering growth factor receptor-bound protein 2 (GRB2), SOS1 or RAF1 proteins 
(Beenken et al., 2009). Other modulators are also present, such as MAPK 
phosphatase 3 (MPK3), a universal inhibitor of receptor tyrosine kinases that acts in 
FGF-pathway by dephosphorylating ERK (Beenken et al., 2009, Turner et al., 2010). 
Similar expression to FGFs (SEF) can also antagonize FGF-signaling through 
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modulation of MAPK pathway (Ornitz et al., 2015a, Turner et al., 2010). In contrast 
to inhibitory proteins, fibronectin-leucine-rich transmembrane protein family 
members (FLRT1 – FLRT3) are positive regulators of FGFR signaling that can 
enhance the FGF-mediated signaling (Wesche et al., 2011). A simplified image of 
the FGFR dimer and the pathways it activates is presented in the Figure 1. 
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Figure 1.  Basic structure of FGFR dimer and summary of FGFR signaling. AKT = protein kinase 
B, Ca2+ = calcium ion, DAG = phosphatic acid, FGF = fibroblast growth factor, FGFR = 
fibroblast growth factor receptor, FRS2 = fibroblast growth factor receptor substrate 2, 
GAB1 = GRB2-associated-binding protein, GRB2 = Growth factor receptor-bound 
protein 2, Ig = immunoglobulin, IP3 = inositol trisphosphate, MAPK = mitogen-activated 
protein kinase, MEK = mitogen-activated protein kinase kinase, PIP2 = 
phosphatidylinositol 4,5-bisphosphate, PI3K = phosphoinositide 3-kinases, PKC = 
protein kinase C, PLCγ = phospholipase gamma,  Raf = RAF proto-oncogene, Ras = 
Ras GTPase, SPRY = sprouty protein. The figure is based on the following publications: 
Andre et al., 2015, Beenken et al., 2009, Ornitz et al., 2015a, Turner et al., 2010, Ornitz 
et al., 2015b. 
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2.3.2 FGFR genetic alterations in breast cancer 
The FGF/FGFR pathway is often dysregulated in cancer (Perez-Garcia et al., 2018, 
Babina et al., 2017, Helsten et al., 2015, Parish et al., 2015, Dienstmann et al., 2014), 
and elevated or activated FGFR expression is associated with increased risk of breast 
cancer (Andre et al., 2015, Babina et al., 2017, De Luca et al., 2017, Fearon et al., 
2013). A meta-analysis was conducted to evaluate the expression of receptor tyrosine 
kinases (RTKs) in breast cancer and their effect on survival (Templeton et al., 2014). 
The RTKs with worst prognosis were FGFR2 and FGFR3, followed by epidermal 
growth factor receptor (EGFR) (Templeton et al., 2014). FGFRs are proto-oncogenes 
that can be activated in cancer by gene amplifications (66%), mutations including 
single nucleotide polymorphisms (26%), and chromosomal translocations and gene-
fusions (8% of the alterations) (Katoh et al., 2014, Perez-Garcia et al., 2018, Andre 
et al., 2015, Parker et al., 2014). In breast cancer, about 18% of patients have one of 
these aberrations in FGFR genes (Helsten et al., 2016). The frequency of alterations 
in FGFR1 – 4 are 3.5%, 1.5%, 2% and 0.5%, respectively (Helsten et al., 2016). 
Furthermore, about 5% of patients have multiple aberrations (Porta et al., 2017), and 
some patients may also have alterations in the downstream signaling molecules from 
FGFRs such as AKT, PI3K and PLCγ (Mikhaylenko et al., 2018). In fact, changes 
in FGFR1 and FGFR2 are considered as important drivers of oncogenesis (Yersal et 
al., 2014, Turner et al., 2010). These mutations usually lead to constitutively active 
receptors and ligand-independent or prolonged signaling by increasing receptor 
affinity to its ligands, affecting the hydrogen bonds that keep the receptor in active 
conformation, deleting of the last exon that results in a truncated, active receptor, 
and inducing changes in the ATP-binding pocket (Turner et al., 2010, Brooks et al., 
2012, Mikhaylenko et al., 2018).  
The increased signaling can also occur via loss of negative regulators (Brooks et 
al., 2012). For example, loss of SPRY1, SPRY2 and SEFs have been observed in 
breast cancer (Brooks et al., 2012). Gene fusions where TK domain of FGFR is fused 
with another gene can also result in constitutively active receptors (Parker et al., 
2014). Furthermore, these fusion receptors are not negatively regulated or do not 
undergo lysosomal degradation leading to increased signaling (Wesche et al., 2011). 
FGFs are also overexpressed in breast cancer. FGF1 and FGF2 are expressed in 
almost all breast tumors (Penault-Llorca et al., 1995, Parish et al., 2015, Slattery et 
al., 2013, Giulianelli et al., 2019, Todorovic-Rakovic et al., 2017), while expression 
of FGF5, FGF6, FGF7 and FGF9 are more case restricted (Penault-Llorca et al., 
1995, Parish et al., 2015). In addition, FGF8 is an oncogene (Mattila et al., 2007) 
that increases angiogenesis (Mattila et al., 2001) and migration and invasion of breast 
cancer cells (Ruohola et al., 2001). Increased expression or activity of FGFs can 
cause hyper-activation of signaling pathways leading to development of cancer, 
increased tumor growth due to increased proliferation and/or pro-survival signals by 
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activation of anti-apoptotic pathways of PI3K/AKT or STAT signaling, development 
of resistance to therapies, and formation of metastases (Perez-Garcia et al., 2018, 
Andre et al., 2015, Turner et al., 2010). As an example, FGF2 produced by stromal 
cells can activate malignant epithelial cells in both auto- and paracrine manner (Jain 
et al., 2012). Many tumors with FGFR mutations have mutations also in FGFR-
related signaling pathways (Turner et al., 2010).  
Even though FGFRs are one of the most commonly altered genes in cancer, it is 
still not clear whether they can solely cause the malignant transformation of 
epithelial cells. In rodent models, FGFR alterations have been seen to cause 
malignant growth of mammary epithelial cells. In humans, the tumors are examined 
late when typically there are multiple mutations present. It is possible that also in 
humans, malignant growth can be initiated by FGFR alterations, but the tumors soon 
acquire multiple mutations to enable rapid growth. Interestingly, FGFRs are 
important for the skeletal development and mutations in FGFR1 – 3 lead to skeletal 
dwarfism, craniosynostosis, and skeletal overgrowth syndromes (Ornitz et al.,2015). 
These skeletal defects are most common disorders caused by FGFR alterations. 
This thesis concentrates on FGFRs in breast cancer, but FGFRs are also altered 
in many other cancers such as cholangiocarcinoma, urothelial, ovarian and squamous 
cell lung cancer (Porta et al., 2017, Helsten et al., 2016). Of these, several FGFR 
inhibitors are in pivotal, phase III clinical trials in cholangiocarcinoma. Alterations 
in different FGFRs in breast cancer are discussed in the following chapters, showing 
examples on how altered FGFR signaling can affect tumor growth. 
2.3.3 FGFR1 alterations 
FGFR1 is one on the most commonly amplified genes in breast cancer (Jain et al., 
2012, Perez-Garcia et al., 2018). About 7.5 – 17% of all breast cancer patients have 
FGFR1 amplification in their tumors (Andre et al., 2015, Katoh et al., 2014, Turner 
et al., 2010). FGFR1 amplifications are common in luminal B breast cancers, being 
found in 16 – 27% of patients (Turner et al., 2010, Yersal et al., 2014, Ornitz et al., 
2015a, Turner et al., 2010, Perez-Garcia et al., 2018, Piasecka et al., 2019, Shi et al., 
2016). FGFR1 amplifications are also observed in other breast cancer subtypes. In 
ER+ breast cancers they are independent predictors of poor overall survival (Andre 
et al., 2015, Jain et al., 2012, Turner et al., 2010). FGFR1 gene (8p11.23) is also co-
amplified with other genes. For example, co-amplifications of FGFR1 and CyclinD1 
decrease survival of patients (Andre et al., 2015, Jain et al., 2012). Other co-
amplification are found in the chromosome 11 that contains for example CyclinD1, 
FGF3, FGF4 and FGF19 (Perez-Garcia et al., 2018). FGFR1 may also be exclusively 
amplified with some genes. For example, FGFR1 and HER2 amplifications are 
usually not observed together in a tumor, suggesting that these pathways are 
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competing (Turner et al., 2010). However, when FGFR1 and HER1/2 amplification 
are observed in the same tumor, these patients have more distant metastases, 
recurrence and decreased disease-free survival (Chen et al., 2018). Furthermore, 
FGFR1 suppresses PR expression and FGFR1 tumors are likely to be PR negative 
(Turner et al., 2010). Some FGFR1 amplifications are also reported in TNBC (Andre 
et al., 2015, Jain et al., 2012, Turner et al., 2010) where FGFR1 is associated with 
poor overall survival (Cheng et al., 2015).  
Besides amplifications, point mutations such as S125L (Andre et al., 2015) and 
single nucleotide polymorphism (SNPs) rs17182023, rs17175624 and rs10958704 
(Wu et al., 2018) have been observed in FGFR1. FGFR1 and transforming acidic 
coiled-coil containing protein 1 (TACC1) fusions have been found in breast cancer, 
leading to continuously active receptor (Ornitz et al., 2015a).  
Many breast cancer cell lines have elevated FGFR1 mRNA expression (Andre 
et al., 2015). FGFR1 may be important also in non-amplified cancers because it 
downregulates D-type cyclins, which increases proliferation (Turner et al., 2010). 
FGFR1 may also promote development of breast cancer (Perez-Garcia et al., 2018). 
This is supported by the findings from FGFR1 transgenic mice, where FGFR1 
activation leads to epithelial cell proliferation and invasive breast lesions (Jain et al., 
2012, Welm et al., 2002). Also, pharmacologically induced FGFR1 activation 
induces malignant changes in mammary epithelium, including invasive lesions and 
vascular branching (Welm et al., 2002, Turner et al., 2010). These findings suggest 
that FGFR1 is an important mediator in the malignant transformation of mammary 
epithelium.  
2.3.4 FGFR2 alterations 
Genome-wide association studies have identified FGFR2 as a susceptibility gene for 
breast cancer (Turner et al., 2010, Agarwal et al., 2014). Increased expression of 
FGFR2 is a prognostic factor for breast cancer that predicts poor overall and disease-
free survival in patients (Andre et al., 2015).  
FGFR2 gene (10q26.13) is amplified only in about 1% of all breast cancers 
(Andre et al., 2015, Katoh et al., 2014, Perez-Garcia et al., 2018). It is most 
commonly amplified in TNBC, where it is found in about 4% of tumors (Andre et 
al., 2015, Katoh et al., 2014, Jain, Turner 2012, Perez-Garcia, Munoz-Couselo et al., 
2018). TNBC tumors are sensitive to FGFR-inhibition both in vitro and in vivo (Jain 
et al., 2012). FGFR2 gene fusion with Putative adenosylhomocysteinase 2 
(AHCYL1), bicc family RNA binding protein 1 (BICC1), AF4/FMR2 family 
member 3 (AFF3), and TACC3 have been found in breast cancer (Ornitz et al., 
2015a). Also FGFR2 copy number variations (CNVs) are present in breast cancer 
(Reintjes et al., 2013).  
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Mutations are more common in FGFR2 gene compared to other genetic 
alterations in breast cancer, and they are most common in ER+ breast cancer. 
Furthermore, SNPs in FGFR2 increase especially the risk for ER+ breast cancer 
(Turner et al., 2010). FGFR2 SNPs (rs2981582, rs1219648, rs2420946 and 
rs2981579) are associated with increased breast cancer risk especially in ER and/or 
PR positive cancers (Andre et al., 2015, Jain et al., 2012). Of these mutations, 
rs10736303 is located in ER binding site (Katoh et al., 2014). Also, a point mutation 
(R203C) has been found in FGFR2 (Andre et al., 2015). Interestingly, FGFR2 
mutations have also been found in BRCA2 mutated breast cancers (Beenken et al., 
2009), and in some cases BRCA2 mutation overlaps with FGFR2 rs2981575 (Katoh 
et al., 2014). Additionally, an association has been identified between FGFR2 
(rs2981582 C>T) and MAP3K1 (rs889312 A>C) gene polymorphisms in breast 
cancer (Dankova et al., 2017). Two meta-analyses evaluated the association between 
FGFR2 SNPs and breast cancer risk (Cui et al., 2016, Zhang et al., 2017). In one 
analysis, 53 studies were enrolled and they included 23 variants in FGFR2, and the 
10 most common of them (rs1078806, rs11200014, rs1219648, rs2420946, 
rs2981578, rs2981579, rs2981582, rs3135718, rs10736303, and rs3750817) were all 
associated with breast cancer risk (Cui et al., 2016). The other meta-analysis 
evaluated FGFR2 polymorphism (rs2981582, rs2420946 and rs2981578) on breast 
cancer risk from 35 studies, and the results showed that all these variants were 
associated with an increased risk of developing breast cancer (Zhang et al., 2017). 
The mutations in FGFR2 gene and their association to breast cancer are summarized 
in the review by Lei and Deng (Lei et al., 2017).  
Besides genetic alterations, FGFR2 is overexpressed in about 5 – 10% of breast 
cancers (Reintjes et al., 2013). FGFR2 amplification has been observed in breast 
cancer cell lines MFM223 and SUM52PE, where the survival of the cells depends 
on FGFR2 expression and kinase activations (Andre et al., 2015). Amplification in 
cell lines led to ligand-independent constitutively activated receptor (Jain et al., 
2012). In addition, in vitro studies have shown that FGFR2 activated by FGF7 can 
induce resistance to tamoxifen by inducing changes in ER phosphorylation, 
ubiquitination and degradation, leading to resistance to endocrine therapies in 
patients (Turczyk et al., 2017). Furthermore, FGFR2 counteracts estrogen effects on 
breast cancer by affecting ESR1 and partly inducing estrogen-independent growth 
(Campbell et al., 2016). Also, studies in transgenic mice have shown that FGFR2 b-
isoform regulates breast morphogenesis (Jain et al., 2012). 
2.3.5 FGFR3 alterations 
FGFR3 expression in breast cancer cells is observed in about 40% of invasive breast 
cancers, and to correlate with decreased overall survival (Kuroso et al., 2010). 
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FGFR3 is amplified in less than 1% of breast cancers (Perez-Garcia et al., 2018). A 
FGFR3-TACC fusion is described in TNBC (Shaver et al., 2016). Mutations in 
FGFR3 are associated with breast cancer risk in patients with BRCA1/2 mutation, 
whereas mutations in FGFR3 are uncommon in BRCA1/2-negative patients with 
hereditary breast cancer (Bergman et al., 2009). SNP rs743682 in FGFR3 is 
associated with breast cancer risk (Agarwal et al., 2014).  
Increased expression of FGFR3 is observed in tamoxifen-resistant breast tumors 
(Tomlinson et al., 2012). This finding was also verified in vitro by a constitutively 
active mutant of FGFR3 expressed in MCF7 breast cancer cells, where the activation 
reduced sensitivity to tamoxifen, followed by activation of MAPK, PI3K and PLCγ 
pathways (Tomlinson et al., 2012). Studies on breast cancer samples and xenografts 
with tumors expressing FGFR2 and FGFR3 show correlation with hormonal status, 
indicating that these receptors are important in regulating hormone-responsive breast 
cancers (Cerliani et al., 2012).  
2.3.6 FGFR4 alterations 
FGFR4 gene (5q35.2) amplifications are found in 2 – 10% of breast cancers, and 
mainly in ER and PR positive breast cancers (Andre et al., 2015, Ornitz et al., 2015a, 
Perez-Garcia et al., 2018). However, elevated mRNA expression of FGFR4 is found 
in about 30% of breast cancers (Andre et al., 2015, Perez-Garcia et al., 2018), and 
FGFR4 expression correlates with HER2 expression (Andre et al., 2015, Cerliani et 
al., 2012). In recurrent breast cancer, increased expression of FGFR4 correlates with 
tamoxifen insensitivity (Beenken et al., 2009), and the expression is increased in 
distant metastasis in invasive lobular carcinoma (Levine et al., 2019). 
A SNP that leads to long-lasting activity of the receptor has been found in the 
transmembrane domain of FGFR4 gene (Andre et al., 2015, Jain et al., 2012). This 
change increases cell motility in vitro and tumor formation and progression of the 
disease in vivo (Andre et al., 2015). An activating point mutation in FGFR4 (Y367C) 
results in constituently active receptor and activates MAPK-signaling pathway in 
MDA-MB-453 cells (Andre et al., 2015). Another point mutation in FGFR4 
(G388R) is linked to poor prognosis in breast cancer (Turner et al., 2010). 
2.4 Targeting FGFRs in breast cancer 
2.4.1 Development of FGFR targeting drugs 
As seen from the paragraphs above, FGFRs are altered in cancer, which also 
increases the sensitivity of these tumors to FGFR inhibition. FGFR aberrations may 
increase tumor growth, induce resistance to therapies such as hormonal and targeted 
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therapies, and decrease survival of patients (Perez-Garcia et al., 2018, Hierro et al., 
2015). Additionally, targeting FGFR-pathway could be beneficial for so-called 
“two-sided” inhibition, which means that such inhibitors could inhibit the cross-talk 
between stromal and tumor cells (Giacomini et al., 2016). This has made FGFRs a 
possible target for drug discovery. The FGF/FGFR pathway can be targeted by 
different approaches. These include inhibition of a) ligand binding by FGF ligand 
traps (for example FP-1039), b) the FGFR extracellular domain by antibodies (for 
example GP369 and MGFR1877S), or c) intracellular activity by small molecule 
inhibitors (examples in the following chapters) (Perez-Garcia et al., 2018, Porta et 
al., 2017, Dieci et al., 2013). Ligand traps are small molecule mimetics that have 
FGF binding/neutralizing capacity (Presta et al., 2017). Antibodies can have two 
main mechanisms of action. They either block ligand binding or prevent receptor 
dimerization, both resulting in inhibition of receptor activation (Porta et al., 2017). 
The mechanism of action for small molecule inhibitors is discussed separately later. 
One additional mechanism for possible inhibitory compounds would be to block 
effector proteins of the FGF/FGFR pathway, but this approach has resulted in major 
adverse effects because many of these proteins are involved in fundamental 
processes also in non-malignant cells (Perez-Garcia et al., 2018).  
Currently available small molecule FGFR inhibitors can be divided into non-
FGFR selective inhibitors (dovitinib, nintedanib, ponatinib, and lucitanib) and FGFR 
selective inhibitors (BGJ398, AZD4547, PD173074, and JNJ-42756493) (Porta et 
al., 2017). Non-selective FGFR inhibitors target also other receptor tyrosine kinases 
with structural similarity such as VEGFR and PDGFR, whereas FGFR selective 
inhibitors only target FGFRs. FGFR inhibitors and their target receptors are 
summarized Perez-Garcia and co-workers (Perez-Garcia et al., 2018). The benefit of 
non-selective inhibitors is a broad inhibition profile of kinases with similar function 
than FGFRs. For example, a non-selective FGFR inhibitor that also inhibits VEGFR 
could have a better efficacy in inhibiting angiogenesis (Porta et al., 2017). However, 
these inhibitors typically have lower binding affinity to FGFRs and increase the 
adverse effects in patients due to wider inhibitor profile (Porta et al., 2017). 
Additionally, a second generation of FGFR inhibitors have been developed, 
including for example the irreversible inhibitors 2 (FIIN-2) and 3 (FIIN-3) (Tan et 
al., 2014). FIIN2 and -3 inhibit the proliferation of cells dependent upon the 
gatekeeper mutations of FGFR1 or FGFR2, which can overcome the resistance of 
first-generation FGFR inhibitors (Tan et al., 2014). 
FGFRs share a large structural similarity, but specific FGFRs can be targeted by 
selective antibodies. With small molecule inhibitors selective targeting is 
challenging and for that there are no inhibitors that would specifically inhibit only 
one of the FGFRs (Lei et al., 2017). It is still possible to develop inhibitors with 
higher binding affinity for example to FGFR1 or FGFR2 (Lei et al., 2017).  However, 
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FGFR4 is structurally different from the other receptors, and typically inhibitors 
have a lower binding affinity to FGFR4 (Jain et al. 2012). However, FGFR4 specific 
inhibitors have also been developed, such as FGF401 (Weiss et al., 2019) and 
BLU9931 (Hagel et al., 2015). 
2.4.2 FGFR inhibitors investigated in breast cancer 
Examples of FGFR inhibitors and antibodies currently investigated for breast cancer 
are briefly described in this chapter. Of these, PD173074, TKI258 (dovitinib), 
BGJ398, and AZD4547 are described in more detail in the upcoming chapters as 
they have been studied in this thesis project. Ongoing clinical trials for these 
compounds are summarized in Table 2 and by summarized in Sobhani and co-
workers (Sobhani et al., 2018). Additionally, FGFR inhibitors have been studied in 
other cancers with FGFR alterations (Holmstrom et al., 2019).  
Nintedanib is a non-selective FGFR inhibitor that targets FGFR1-3, VEGFR1-3, 
PDGFR and Flt3 (Porta et al., 2017). It has shown promising results with a variety 
of tumors including TNBC in preclinical models (Liu et al., 2017, Reguera-Nunez 
et al., 2019), and also potential anti-tumor effects in combination with programmed 
death ligand 1 (PD-L1) antibody (Reguera-Nuñez et al., 2019). Phase 0/I clinical 
trial has been reported (Quintela-Fandino et al., 2019), and further clinical trials are 
ongoing for breast cancer. 
Ponatinib is a non-selective FGFR inhibitor targeting Bcr-Abl, VEGFRs, 
FGFRs, TIE2 and Flt3 (Porta et al., 2017). It has shown efficacy in breast cancer cell 
lines having FGFR1 – FGFR4 alterations, and it has the potency to inhibit all four 
FGFRs. Because ponatinib targets Bcr-Abl kinase it has been widely studied in 
hematological cancers, but recently, results have been published also in solid tumors 
(Musumeci et al., 2018, Bauer et al., 2018). Ponatinib is currently studied in clinical 
trials in solid tumors with FGFR alterations (Porta et al., 2017). 
Lucitanib (E-3810) inhibits FGFR1/2, VEGFR1-3 and PDGFRα/β, and is 
currently undergoing phase I/II clinical trial for breast cancer, including metastatic 
breast cancer (Porta et al., 2017, Criscitiello et al., 2015, Andre et al., 2015, Soria et 
al., 2014). Preclinical data suggests antitumor efficacy in a FGFR1 and FGFR2 
amplified xenograft model, partially mediated by inhibition of angiogenesis (Perez-
Garcia et al., 2018, Guffanti et al., 2017), and tumor regression in combination with 
paclitaxel in a TNBC model (Andre et al., 2015, Bello et al., 2013). A phase Ib study 
evaluated the maximum tolerated dose and safety profile of lucitanib in metastatic 
breast cancer (Campone et al., 2019).  In breast cancer patients with FGFR 
aberrations, the objective response rate was 50% and progression free survival was 
increased by about 40 weeks (Porta et al., 2017). Phase II clinical trials are currently 
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ongoing with metastatic breast cancer patients (Porta et al., 2017, Hui et al., 2018, 
Campone et al., 2018).  
Erdafitinib (JNJ 42756493) is an oral pan-FGFR inhibitor targeting FGFR1 – 
FGFR4 (Porta et al., 2017, Perez-Garcia et al., 2018, Andre et al., 2015). It has anti-
tumor effects in FGFR wild-type and FGFR2 amplified cells in vitro and in vivo, 
where it induces cell death and decreases cell survival (Porta et al., 2017, Karkera et 
al., 2017). It is currently in phase I clinical trial for advanced solid tumors with 
promising results. Forty percent of patients had stable disease, including patients 
with FGFR1 amplified breast cancer (Porta et al., 2017, Perez-Garcia et al., 2018). 
Erdafitinib (Balversa) was earlier this year approved by FDA for treatment of 
metastatic bladder cancer patients with genetic alterations in FGFR2 (Marandino et 
al., 2019). 
Table 2.  Current status of FGFR inhibitors TKI258, BGJ398 and AZD4547 in clinical 
development for breast cancer, either ongoing or completed. Data obtained from 
clinicaltrials.gov on July 20, 2019.  
FGFR 
inhibitor 
Condition Title Compound(s) Clinicaltrials.gov 
identifier 
TKI258 
 
Metastatic 
breast 
cancer 
Safety and efficacy of 
TKI258 in FGFR1 
Amplified and Non-
amplified Metastatic 
HER2 Negative Breast 
Cancer 
TKI258 NCT00958971 
Breast 
cancer 
TKI258 for Metastatic 
Inflammatory Breast 
Cancer Patients 
TKI258 NCT01262027 
BGJ398 Advanced/ 
metastatic 
solid tumors 
Phase 1b Trial of 
BGJ398/BYL719 in 
Solid Tumors 
BGJ398 NCT01928459 
AZD4547 
 
Breast 
cancer 
AZD4547 & 
Anastrozole or 
Letrozole (NSAIs) in 
ER+ Breast Cancer 
Patients Who Have 
Progressed on NSAIs 
(RADICAL) 
AZD4547 and 
anastrozole or 
letrozole 
NCT01791985 
ER positive 
breast 
cancer 
Safety and Efficacy of 
AZD4547 in 
Combination With 
Fulvestrant vs. 
Fulvestrant Alone in 
ER+ Breast Cancer 
Patients 
AZD4547 and 
Exemestane or 
Fulvestrant 
 
NCT01202591 
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2.4.3 PD173074 
PD173074 is among the first of first-generation FGFR inhibitors. It inhibits mainly 
FGFR1 and FGFR3 (Andre et al., 2015). It has been studied in many breast cancer 
cells lines where it inhibited FGFR mediated signaling and resulted in many anti-
tumor effects.  
In a FGFR expressing syngeneic tumor model, PD173074 decreased tumor 
growth and induced apoptosis in a dose-dependent manner (Andre et al., 2015, Ye 
et al., 2014). In PD743074 treated tumors, increased expression of the pro-apoptotic 
protein survivin and increased ratio of Bax/Bcl-2 were observed, explaining the 
increase in apoptosis (Ye et al., 2014). Additionally, PD173074 induced anoikis in a 
FGFR1-amplified cell model (Chen et al., 2016) and decreased microvessel density, 
which could contribute to the decreased tumor growth (Ye et al., 2014). PD173074 
blocks migration and invasion in vitro, which led to decreased formation of lung 
metastases in vivo. Supporting these findings, PD173074 treatment is associated with 
morphological changes in EMT cell lines expressing FGFR1, including spindle- to 
cobble stone -like change in shape (Nguyen et al., 2013). Also, expression of MMPs 
and Snail1 and 2 that are involved in EMT, are decreased with treatment of 
PD173074, indicating that PD173074 could inhibit EMT and prevent formation of 
metastases (Nguyen et al., 2013). Interestingly, PD173074 is also associated with 
increased number of CD4+ and CD8+ T cells in the spleen and tumors (Andre et al., 
2015, Ye et al., 2014), and decreases the number of myeloid-derived suppressor cells 
(MDSCs) indicating that the compound has also immunological effects (Ye et al., 
2014). 
PD173074 has also been studied in basal-type breast cancer models. About half of 
basal-type breast cancer cell lines and breast cancers express FGF2 (Sharpe et al., 
2011). Silencing of FGF2 from these cell lines results in decreased FGFR-mediated 
signaling and decreased proliferation, suggesting autocrine signaling of FGF2 
(Sharpe et al., 2011). This signaling is blocked by PD173074, which reduces tumor 
growth in a xenograft model (Andre et al., 2015, Sharpe et al., 2011).  
Generally, TNBC cell lines are more sensitive to FGFR inhibition than other 
breast cancer cell lines (Sharpe et al., 2011). In TNBC cell lines, PD173074 inhibits 
MAPK and PI3K/AKT signaling (Andre et al., 2015, Koziczak et al., 2004). 
PD173074 decreases proliferation in TNBC cell lines and the effect is more profound 
in anchorage-independent 3D culture conditions (Sharpe et al., 2011). PD173074 
causes cell cycle arrest to G1 state, downregulates D1 and D2 cyclin expression, and 
inhibits cyclin D to cdk4 activity (Andre et al., 2015, Sharpe et al., 2011, Koziczak 
et al., 2004). These results show that D cyclins are important in FGFR-driven cancers 
(Koziczak et al., 2004).  
In a HER2 positive model that was induced to become resistant to HER2 targeted 
therapies, a loss of HER2 expression and an amplification in FGFR2 were observed 
Review of the Literature 
 37 
(Azuma et al., 2011). This change in expression sensitized the cells to PD173074, 
and the cells were 10 000 times more sensitive to the compound compared to 
parental cells. PD173074 decreased phosphorylation of FGFR2 in the model, and 
induced apoptosis in vitro.  
Despite its many potential anti-tumor effects, PD173074 is not undergoing 
clinical development, and it has been replaced with second-generation FGFR 
inhibitors. It is mostly used in preclinical studies for its high potential to target 
FGFR1. 
2.4.4 TKI258 (dovitinib) 
Dovitinib is an oral non-selective FGFR inhibitor that binds to FGFR1, VEGFR1 – 
VEGFR3, c-KIT, fms-related tyrosine kinase 3 (FLT3) and PDGFRb (Andre et al., 
2015, Porta et al., 2017, Perez-Garcia et al., 2018). Additionally, some activity 
against FGFR2 and FGFR3 have been observed in preclinical models (Porta et al., 
2017).  
In 4T1 cell line with constitutively active FGFR-pathways and 67NR cell line 
with FGFR2 and FGFR3 expression, dovitinib decreases phosphorylation of FRS2 
and phosphorylation of downstream proteins of ERK1/2, AKT, and PLCγ (Andre et 
al., 2015, Dey et al., 2010, Porta et al., 2017). Additionally, dovitinib decreases 
phosphorylation of FRS2 and ERK/MAPK in FGFR1- and FGFR2-amplified cell 
lines (Andre et al., 2015). This inhibition in FGFR-mediated signaling blocks 
proliferation and growth of the cells (Andre et al., 2015, Dey et al., 2010). 
Additionally, dovitinib increases apoptosis in the 4T1 model by blocking the 
PI3K/AKT pathway (Dey et al., 2010). Also, the effects of dovitinib have been 
studied in co-culture models where no effects on cancer-associated fibroblasts 
(CAFs) were observed (Dittmer et al., 2011). 
Dovitinib prevented FGFR-mediated signaling by blocking FRS2 and ERK1/2 
signaling in in vivo tumor models (Andre 2015). Only one dose of TKI258 rapidly 
lowered FRS2 phosphorylation and ERK1/2 and AKT activity in the tumors (Dey et 
al., 2010). Dovitinib decreased tumor growth in 4T1, 67NR, and in FGFR1- and 
FGFR2-amplified models (Andre et al., 2015, Dey et al., 2010, Andre et al., 2013). 
This anti-tumor activity was mediated through direct inhibition of FGFR and 
PDGFR and partially caused by inhibition of angiogenesis (Dieci et al., 2013). No 
effects were observed for dovitinib in models with no changes in FGFR pathways, 
such as the MMTV-PyMT breast cancer model (Hernandez-Agudo et al., 2016). 
Importantly, long-term treatment of dovitinib decreased lung metastases in 4T1 and 
67NR tumor-bearing mice (Andre et al., 2015, Dey et al., 2010), which could be 
mediated through downregulation of MMPs (Dey et al., 2010). Additionally, 
dovitinib inhibits CAF-induced invasion by inhibiting secretion of CCL2, CCL5 and 
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VEGF, and the PI3K/Akt/mTOR signaling pathway (Zang et al., 2015). When 
dovitinib was combined with the PI3K/mTOR inhibitor NVP-BEZ235 or the pan-
ErbB inhibitor AEE788 in the 4T1 and 67NR breast cancer models, it blocked the 
FGFR/FRS2/ERK and PI3K/Akt/mTOR pathways, further inhibited tumor growth, 
and blocked formation of lung metastases (Andre et al., 2015, Issa et al., 2013). 
Dovitinib has proceeded to phase II clinical trials in breast cancer. It was studied 
as a single agent in HER2 negative metastatic patients with amplification of FGFR1 
(Perez-Garcia et al., 2018, Andre et al., 2015, Andre et al., 2013). Dovitinib was 
given orally as a dose of 500 mg/d (5-days-on/2-days-off) in 28-day cycles. Twenty 
five percent of FGFR1-amplified patients experienced either partial response or 
stable disease for more than 6 months (Dieci et al., 2013, Andre et al., 2013). Despite 
of these promising results, the trial did not meet pre-defined efficacy endpoints 
(Andre et al., 2015, Andre et al., 2013). The study revealed that amplifications in 
FGFR2 and FGF3 might be beneficial in evaluating who will benefit from FGFR-
targeted treatments (Dieci et al., 2013). This study led to another study in HER2 
negative and hormone receptor positive metastatic breast cancer in combination with 
fulvestrant (Dieci et al., 2013). The median progression free survival was 10.9 
months in dovitinib treated patients vs 5.5 months in patients treated with placebo 
(Musolino et al., 2017). Dovitinib is also evaluated in a phase II study in patients 
with metastatic FGFR1 amplified and HER2 negative inflammatory breast cancer, 
and in a phaseI/II study of dovitinib in combination with aromatase inhibitors in 
patients with metastatic breast cancer with resistance to prior aromatase inhibitor 
therapy (Dieci et al., 2013, Andre et al., 2015). 
Dovitinib treatment is associated with adverse effects, including diarrhea, 
nausea, vomiting and fatigue that affect about 90% of the patients (Porta et al., 2017). 
Other adverse effects include cardiovascular events, asthenia, gastrointestinal 
disorders, abnormal values in liver function tests, and lymphopenia (Perez-Garcia et 
al., 2018, Dieci et al., 2013, Musolino et al., 2017). Interestingly, 
hyperphosphatemia, which is a common off-target effect for FGFR inhibitors, was 
not observed in dovitinib treated patients (Dieci et al., 2013). Despite of these 
adverse effects, dovitinib is considerably well-tolerated in heavily pre-treated 
patients (Andre, Cortes 2015), also as a combination partner with other therapies 
(Musolino et al., 2017).  
2.4.5 BGJ398 (infigratinib) 
BGJ398 is an oral selective pan-FGFR tyrosine kinase inhibitor that also inhibits 
FGFR1 – FGFR3 (Dieci et al., 2013). BGJ398 decreases activation of FGFR1 and 
phosphorylation of MEK/ERK signaling in FGFR1-amplified breast cancer cells 
(Golfmann et al., 2018). MCF10A cells with higher FGFR1β levels are more 
Review of the Literature 
 39 
sensitive to BGJ398 compared to the same cells with high FGFR1α levels (Zhao et 
al., 2019). Only cells with FGFR1β-expression had enhanced cell growth and 
motility in the model. Expression of FGFR1β is also dominant in a metastatic model 
where pharmacological inhibition of FGFR1 by BGJ398 decreases lung metastases 
(Wendt et al., 2014). 
BGJ398 decreases proliferation (Perez-Garcia et al., 2018) and the number of 
lung metastases (Sahores et al., 2018) in breast cancer models with FGFR 
expression. Treatment with BGJ398 leads to rapid tumor regression in a 
transplantable FGFR1 mammary tumor model, leaving a non-palpable mass of 
dormant tumor cells organized into a luminal and basal epithelial layer similar to the 
normal mammary gland, but surrounded by dense stroma with decreased levels of 
MDSCs and tumor vasculature (Holdman et al., 2015). When the treatments were 
stopped, the tumors recurred in 1 to 4 months. The recurrent tumors displayed dense 
stroma with increased collagen, tenascin-C expression, and MDSC infiltration 
(Holdman et al., 2015). Activation of the EGFR pathway was observed in recurrent 
tumors, and inhibition of EGFR with lapatinib in combination with BGJ398 resulted 
in a significant delay in tumor recurrence accompanied by reduced stroma (Holdman 
et al., 2015). Treatment of mice with bone metastases with BGJ398 led to reduced 
osteoclast activity and bone destruction, demonstrating that tumor cell -derived 
FGFs enhance osteoclast function and contribute to the formation of metastatic 
lesions in the model (Aukes et al., 2017). 
BGJ398 has been studied in a phase I trial. It was evaluated at doses from 5 to 
150 mg/d once daily and also 50 mg twice daily given continuously in 28-day cycles 
for patients with advanced solid tumors with FGFR alterations (Perez-Garcia et al., 
2018). In later clinical trials, 10 of 32 patients (31%) treated with BGJ398 had stable 
disease. Additionally, 26 breast cancer patients with pre- and post-treatment target 
lesion measurements had tumor reduction (Perez-Garcia et al., 2018).  
In general, BGJ398 is well tolerated and common adverse events include 
hyperphosphatemia (82.5%), constipation (50.9%), decreased appetite (45.6%), 
stomatitis (45.6%), and also diarrhea, fatigue, and nausea (Perez-Garcia et al., 2018). 
Other adverse-effects including increase in aspartate aminotransferase and alanine 
aminotransferase levels, hyperphosphatemia and corneal toxicity (Perez-Garcia et 
al., 2018) require interruptions in the dosing schedule to improve tolerability, and 
for this the patients are treated with phosphate binders and diuretics (Perez-Garcia et 
al., 2018, Dieci et al., 2013). Increased serum phosphate levels can be used as a 
biomarker of FGFR inhibition in humans (Wu et al., 2013, Wöhler et al., 2013). 
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2.4.6 AZD4547 
AZD4547 is an oral FGFR selective inhibitor for FGFR1 – FGFR3 (Porta et al., 
2017, Gavine et al., 2012, Perez-Garcia et al., 2018, Andre et al., 2015). It inhibits 
FGFR downstream signaling pathway and induces cytotoxic and cytostatic effects 
(Porta et al., 2017). It has a strong activity against FGFR1, FGFR2, FGFR3, FRS2, 
and PLCγ (Gavine et al., 2012, Porta et al., 2017). AZD4547 inhibits recombinant 
FGFR kinase activity in vitro and suppresses FGFR signaling and growth in tumor 
cell lines expressing FGFR (Gavine et al., 2012). 
AZD4547 has potent anti-proliferative effects and suppresses FGFR/RTK 
signaling in HER2 overexpressing human breast cancer cells (Zhao et al., 2017). To 
study the effects of AZD4547 on mammary development in mammary epithelial cell 
(MEC) populations, MMTV-ErbB2 transgenic mice were administered AZD4547 
for 10 weeks during the 'risk window' for mammary tumor development (Zhao et al., 
2017). AZD4547 inhibited ductal branching and MEC proliferation in vivo, 
supporting the in vitro finding on anti-proliferative properties. AZD4547 
downregulated RTK, mTOR, and Wnt/β-catenin signaling pathways in premalignant 
mammary tissues (Zhao et al., 2017). 
AZD4547 has anti-proliferative effects in a wide range of FGFR-dependent cell 
lines and xenografts models (Perez-Garcia et al., 2018). AZD4547 suppresses FGFR 
signaling and growth in tumor cell lines with deregulated FGFR expression (Dieci 
et al., 2013). In a FGFR3-driven human tumor xenograft model, oral administration 
of AZD4547 was well tolerated and resulted in potent antitumor activity (Dieci et 
al., 2013). In a syngeneic 4T1 model, AZD4547 decreased tumor growth, blocked 
migration and invasion, induced apoptosis, and decreased formation of lung 
metastases (Liu et al., 2014). AZD4547 also increased the number of CD4+ and 
CD8+ T cells and decreased the number of MDSCs in peripheral blood and spleens. 
AZD4547 was also studied in a TNBC bone metastasis model, where it decreased 
tumor-induced osteolytic lesions and suppressed osteoclastogenesis (Kang et al., 
2019). 
AZD4547 is currently evaluated in clinical trials. In a phase II study, patients 
with FGFR1-amplified HER2 negative breast cancer had a 12.5% response rate 
(Porta et al., 2017). In another phase II trial, treatment of patients with FGFR 
amplified tumors with 80 mg of AZD4547 twice daily in a 2-weeks-on/1-week-off 
schedule or continuously, 1/8 (12.5 %) of the patients had partial response (Perez-
Garcia et al., 2018). AZD4547 is being studied in combination with letrozole or 
anastrozole in patients with ER positive tumors who have relapsed on the treatment 
(Andre et al., 2015). AZD4547 is generally well tolerated, with the most common 
adverse events reported being fatigue, hyperphosphatemia, mucositis, nausea, and 
nail changes (Perez-Garcia et al., 2018). AZD4547 is one of promising compounds 
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for cancers with FGFR alterations. However, more studies are needed to determine 
the patient population who will benefit from the treatment (Porta et al., 2017).
 3 Aims 
The main objectives of this thesis were to assess the role of FGFRs in breast cancer, 
and to study the effects FGFR inhibitors in primary and bone metastatic disease, and 
in osteoblasts, using preclinical models. 
 
Specific aims were: 
1. To study the role of FGFRs in the regulation of breast cancer growth 
2. To study the effects of FGFR inhibitors in 2D and 3D breast cancer cell culture 
models and in human breast cancer tissue explants 
3. To study the effects of one FGFR inhibitor, dovitinib, in an experimental 
breast cancer bone growth model in vivo 
4. To study the role of FGFRs in the differentiation of mesenchymal stromal cells 
to osteoblasts  
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4 Materials and Methods 
4.1 FGFR inhibitors 
PD173074 was a gift from Pfizer Pharmaceuticals. DMSO-stocks of TKI258 
(S2769), BGJ398 (S2183) and AZD4547 (S2801) were purchased from Selleck 
Chemicals. For the in vivo study, TKI258 was ordered as a powder, dissolved in 
sterile water, filtered and stored at -20⁰C in single-use aliquots. 
4.2 Cell culture 
4.2.1 Cell lines (I–IV) 
The following cell lines were used: Shionogi 115 (S115, I), MCF-7 (II), MDA-MB-
231(SA) (II), MFM223 (II and III), MSC#6 and MSC#22 (IV). S115 and MCF-7 
cells were purchased from American Type Culture Collection and MFM223 cells 
from Sigma-Aldrich. MDA-MB-231(SA) cells were a gift from Dr. Theresa Guise 
from University of Texas Health Science Center at San Antonio. Immortalized 
mouse mesenchymal stromal cell lines, MSC#6 and MSC#22, were established and 
are reported in subproject IV. The culture conditions are described in the respective 
research articles. 
4.2.2 Transfections (I) 
Transfections of the S115 cell line is described in detail in subproject I. Briefly, 
lentiviral transfection technique using pLKO.1 lentiviral vectors for FGFR1 and 
FGFR2 siRNAs for were used for S115 cells. The siRNA constructs were a gift from 
Dr. Nancy Hynes from University of Basel. The cells were incubated with 
multiplicity of infection medium with lentiviral constructs for 6 h. The medium was 
replaced with normal culture medium containing puromycin, a selection antibiotic. 
Puromycin-resistant pools of cells were used in further studies. 
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4.2.3 Osteoblast differentiation (IV) 
Immortalized mouse mesenchymal stromal cell lines MSC#6 and MCS#22 were 
established and are reported in subproject IV.MSC#6 cells were cultured in 
osteoblast differentiation medium containing 15% iFBS, sodium-β-
glycerophosphate and ascorbic acid in αMEM. The differentiation period was 2 
weeks, and half of the medium was replaced with fresh medium every 3-4 days 
during the differentiation process. 
4.3 In vitro models 
4.3.1 Proliferation and viability (I–II) 
Several proliferation assays were used. 3(H)-thymidine incorporation assay is 
described in subproject I and IncuCyte proliferation assay in subproject II. Briefly, 
in 3(H)-thymidine incorporation assay the incorporation of 3(H)-thymidine to newly 
synthetized DNA was measured as β radiation emitted from the hydrogen. In 
IncuCyte assay, proliferation was measured as increase in confluency in the wells by 
real-time imaging. 
4.3.2 Migration and invasion (II) 
IncuCyte migration and invasion assays were used as instructed by the manufacturer. 
Briefly, in migration assay the cells were allowed to migrate on plastic, and in 
invasion assay the cells were embedded between two layers of rat tail collagen I 
matrix. The wound closure was imaged and analyzed with IncyCyte ZOOM analysis 
software. 
4.3.3 Organoid cultures (II) 
The method for 3D organotypic cultures has been previously described (Harma, 
Virtanen et al., 2010). Briefly, the cells were seeded between two layers of matrigel 
to 30% confluency, with the aim to have organoids formed from single cells. The 
organoids were allowed to form for 2-3 days and thereafter treated for 7-9 days. At 
the end of the experiment the spheroids were stained with calcein/EthD1 (live/dead 
cells, respectively) and imaged with a confocal microscope. The images were 
analyzed with AMIDA software to obtain morphological and quantitative data 
(Härmä et al., 2014). 
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4.4 In vivo models  
4.4.1 Ethical statement (I–III) 
Animal experiments were carried out at the Central Research Laboratory of the 
University of Turku. Ethical approval for animal studies was given by the local ethics 
committee (license number: 2008-05531(I) and 3908/04.10.03/2011 (III)). 
Human breast cancer tissue samples were obtained from Department of Plastic 
and General Surgery at Turku University Hospital (Turku, Finland).  The study was 
carried out with approval from the Ethics Committee of the Hospital district of 
Southwestern Finland and a written consent from the patients (§279, 9/2001). 
4.4.2 Subcutaneous tumor model (I) 
Male athymic nude mice (Envigo) were implanted with 10 mg testosterone releasing 
pellets (Innovative Research of America) before injection of 1x106 S115 cells into 
the lower back of the mice. Tumor growth was followed twice a week by caliper 
measurements until study termination at 4 weeks. 
4.4.3 Intratibial model (III) 
Female athymic nude mice (Envigo) were inoculated with 5x105 MFM223 cells into 
the bone marrow of right proximal tibia. TKI258 treatment was started at 4 weeks 
and the study was terminated at 9 weeks. 
4.4.4 Ex vivo explant cultures (II) 
The method to culture human breast tissue explant has been described (Eigeliene et 
al., 2006). The cultures were treated with FGFR inhibitors for 7 days. At the 
endpoint, tissues were fixed in 10% neutral buffered formalin and proceeded to 
further analysis. 
4.5 Analysis methods 
4.5.1 qRT-PCR (I–IV) 
mRNA was extracted from the cells using RNeasy kit (Qiagen) according to the 
manufacturer’s instructions. cDNA was synthetized with Oligo-dT -primers using 
Maxima RT enzyme (Thermo Fisher Scientific). For qRT-PCR, DyNAmo HS SYBR 
Green qPCR kit (Thermo Fisher Scientific) with gene-specific primers (see original 
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articles I-IV) was used. The samples were run with CFX96 qPCR system (Bio-Rad) 
and the results were analyzed using ΔΔCt-method. 
4.5.2 Western blot (I, II and IV) 
Protein samples were run on 10% SDS-PAGE gel, transferred to Ultra Cruz 
nitrocellulose (Santa Cruz Biotech) or PVDF membranes (Millipore), and incubated 
with primary antibodies at (see original articles I, II and IV) +4°C o/n.  The emitted 
fluorescence (Li-Cor Odyssey® CLx imaging system) or chemiluminescence (ECL 
method, GE Healthcare) were detected to Kodak films (PerkinElmer). 
4.5.3 Immunohistochemistry (I–III) 
Sections were stained with hematoxylin and eosin (HE) or with primary antibodies 
(for proliferation: Ki67 and/or PHH3, for apoptosis: TUNEL, for vasculature: 
PECAM-1) at +4⁰C o/n, and secondary antibody for 1 h at room temperature (see 
original articles I, II and III for details). The chromogenic peroxidase-based staining 
with diaminobenzene (Vector Laboratories) was used with counterstaining with 
Mayer's hematoxylin.  
Sections were scanned with a digital slide scanner (Pannoramic 250 Slide 
Scanner, 3DHistech). For quantifying proliferation results, the number of PHH3 
positive cells per section from the subcutaneous tumors were counted from 5 – 15 
fields of view. From explant cultures, the number of Ki67 positive cells were 
quantified from cancerous area and adjusted to the total number of tumor cells in the 
sections. For quantifying apoptosis, the number of fluorescent cells from TUNEL 
staining were counted. For quantifying vascularization, the length of PECAM-1 
positive capillaries were analyzed from 3 fields of view per tumor. All analyses were 
performed with Image J program. 
4.5.4 Bone biomarkers (III) 
Mouse serum samples were analyzed for tartrate-resistant acid phosphatase 5b 
(TRACP5b, IDS) as a marker of osteoclast number (Alatalo et al., 2000) and 
procollagen I N-terminal propeptide (PINP, IDS) as a marker of bone formation 
(Hale et al., 2007). The assays were performed according to the manufacturer’s 
instructions. 
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4.6 Imaging 
4.6.1 X-ray imaging (III) 
Mice were imaged with X-ray (Faxitron) using settings of 34 kV for 7 seconds. The 
images were analyzed with Image J software by quantifying the area of osteolytic 
lesions in bone. 
4.6.2 PET imaging (III) 
Positron Emission Tomography and CT (PET/CT, Inveon) imaging was performed 
with 5 MBq of [18]F-FDG to visualize metabolic activity of intratibial tumors 2 h 
after injection. PET/CT images were analyzed to obtain metabolically active tumor 
volume.   
4.6.3 pQCT imaging (III) 
Formalin-fixed tumor-bearing tibias were analyzed with peripheral quantitative 
computed tomography (pQCT, Norland Stratec). Scannings were performed at the 
area of trabecular bone 0.7–1 mm below the growth plate to obtain values for 
trabecular and cortical bone mineral density (BMD) and bone mineral content 
(BMC). 
4.6.4 Statistics (I–IV) 
Statistical analysis was performed with GraphPad Prism software (versions 6 and 7). 
All in vitro experiments were repeated at least two times, and the number of 
replicates was at least 3 in each experiment. All in vivo studies were performed two 
separate times. All experiments were analyzed separately and the results of one 
representative experiment are presented. Statistical methods used for each analysis 
are detailed in the figure legends or statistics chapter in the research articles (see 
original articles I-IV).
 5 Results 
5.1 FGFR expression in breast cancer cells and 
patient samples 
FGFRs were differentially expressed in the breast cancer cell lines used in the study. 
Analysis of mRNA levels by qPCR in S115 cells showed highest expression of 
FGFR1, followed by FGFR2 and FGFR3 (I, Figure 1). FGFR4 mRNA was not 
expressed in these cells. MCF-7 cells expressed FGFR4, FGFR1, FGFR2 and 
FGFR3 mRNA in the order of magnitude (II, Figure 1). MDA-MB-231(SA) 
expressed high levels of FGFR4 and FGFR1 mRNA, whereas the expression of 
FGFR2 and FGFR3 mRNA were low (II, Figure 1). MFM223 cells have FGFR1 and 
FGFR2 gene amplifications (Turner et al., 2010), and it was confirmed that MFM223 
cells expressed high levels of FGFR2, FGFR4 and FGFR1 mRNA (II, Figure 1). 
Additionally, increased levels of mRNA of one or several FGFRs in 7/10 samples 
was observed in a small set of human breast cancer tissue samples (II, Figure 5). In 
these samples, FGFR3 and FGFR4 were expressed at the highest levels. 
5.2 Differential effects of FGFRs in breast cancer 
The roles of FGFR1 and FGFR2 in the regulation of growth of S115 cells was 
studied. For this, S115 cells were silenced for either FGFR1 or FGFR2 using 
lentiviral transfections to establish stable cell lines with decreased expression of the 
FGFRs. The established cell lines had low FGFR1 (FGFR1 silencing) and low 
FGFR2 (FGFR2 silencing) mRNA and protein levels, respectively (I, Figure 1). As 
a result of FGFR2 silencing, FGFR1 expression was increased, indicating mutual 
regulation between these receptors. Silencing FGFR1 did not change the expression 
of the other FGFRs. 
FGFR2 silenced cells (named hereafter FGFR1highFGFR2low, named shR2 in 
subproject I) had increased proliferation compared to FGFR1low (named shR1 in 
subproject I) and control (with FGFR levels similar to parental S115 cells, named 
shLacZ in subproject I) cells, as evaluated by 3(H)-thymidine incorporation assay (I, 
Figure 2). FGFR1highFGFR2low cells also had increased expression of cell cycle 
regulatory proteins cyclin D1 and B1, as studied by western blotting (I, Figure 2). 
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FGFR1highFGFR2low cells formed larger tumors in vivo in a subcutaneous model 
compared to tumors formed from FGFR1low or from control cells (I, Figure 3). 
5.3 Inhibition profile of FGFR inhibitors and their 
effects on intracellular signaling 
The effects of TKI258, BGJ398 and AZD4547 on inhibition of FGFR-mediated 
intracellular signaling in FGFR amplified and non-amplified breast cancer cells were 
studied by western blotting. TKI258 decreased phosphorylation of FRS2 and ERK 
at 1 nM concentration in FGFR-amplified cells (II, Figure 1). The effects were not 
so clear on non-FGFR amplified cells with EKR, whereas the decrease in pFRS2 
was observed in non FGFR-amplified cells at 1-10 nM concentrations. BGJ398 
decreased pFRS2 and pERK at 1 nM concentration in FGFR-amplified cells (II, 
Figure 1). Non-FGFR amplified cells responded differentially to BGJ398, as MCF-
7 cells had decreased phosphorylation at 100 nM, whereas no effects were observed 
in MDA-MB-231(SA) cells at any concentrations tested. AZD4547 was equally 
effective in decreasing pFRS2 and pERK in FGFR amplified cells. In non-FGFR 
amplified cells, a decrease was observed at 100 nM concentration in MCF-7 cells 
(II, Figure 1), and no effects were observed in MDA-MB-231(SA) cells. 
5.4 FGFRs differentially regulate proliferation and 
growth of breast cancer cells 
PD173074 decreased the proliferation in FGF8b-treated S115 cells in 3(H)-
thymidine incorporation assay, which occurred regardless of the FGFR silencing in 
the cell lines (I, Figure 2). TKI258 decreased proliferation of FGFR amplified MFM-
223 cells at 100 nM concentration, as analyzed by kinetic proliferation with the 
IncuCyte assay (II, Figure 2). Proliferation was decreased in MCF-7 cells at 10 µM 
and MDA-MB-231(SA) cells at 5 µM concentration. BG398 decreased proliferation 
of FGFR amplified cells at 10 nM concentration (II, Figure 2). In MCF-7 cells, 
proliferation was decreased at 1 µM, and in MDA-MB-231(SA) cells at 5 µM 
concentration. AZD4547 decreased proliferation of FGFR amplified cells at 10 µM 
concentration (II, Figure 2). Decreased proliferation was observed at 5 µM and 10 
µM concentrations in MCF-7 and MDA-MB-231(SA) cells, respectively. 
FGFR amplified cells formed less organized and irregular-shape organoids 
compared to organoids formed from MCF-7 and MDA-MB-231(SA) cells in a 3D 
organotypic culture model (II, Figure 3). TKI258, BGJ398 and AZD4547decreased 
the growth of FGFR amplified organoids at 1 nM concentration (II, Figure 3). 
Decreased growth of MCF-7 and MDA-MB-231(SA) organoids was observed at 5 
µM and 1 µM concentrations of TKI258, respectively (II, Figure 3). BGJ398 
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decreased growth of MCF-7 and MDA-MB-231(SA) organoids at 10 µM and 5 µM 
concentrations, respectively (II, Figure 3). AZD4547 was equally effective in 
organoids formed from non-FGFR amplified cells, and decreased growth was 
observed at 5 µM concentration (II, Figure 3). 
PD173074 treatment decreased the proliferation and growth of 
FGFR1highFGFR2low S115 subcutaneous tumors compared to vehicle treated mice 
(I, Figure 3). In the intratibial tumor model, TKI258 induced a trend towards 
decreased tumor volume and metabolic activity evaluated by [18]F-FDG PET 
imaging at endpoint (III, Figure 1). However, no changes were observed in 
proliferation rate in the tumors evaluated by PHH3 IHC (III, Figure 1). A trend 
towards decreased proliferation was observed in human breast cancer explant 
cultures when treated with FGFR inhibitors (II, Figure 5). As the number of samples 
was very limited, these results can only be considered as preliminary. 
5.5 FGFR inhibitors do not induce apoptosis 
No increase in apoptosis was observed in vitro in monolayer cultures with FGFR 
inhibitors (II), or in FGFR-amplified organoids (II, Figure 3). In organoids formed 
from MCF-7 and MDA-MB-231(SA) cells, increased amount of dead cells 
quantified from live/dead cell stainings were observed with BGJ398 and AZD4547 
at 1 to 5 µM concentrations (II, Figure 3). TKI258 increased the amount of dead cells 
only in organoids formed from MDA-MB-231(SA) cells (II, Figure 3). PD173074 
treatment slightly increased the number of dead cells in tumors with 
FGFR1highFGFR2low expression in the S115 tumor model (I, Figure 5). 
5.6 Other potential effects of FGFR inhibitors: 
angiogenesis, migration and invasion 
No effects were observed on angiogenesis in FGFR1highFGFR2low S115 tumors 
treated with PD173074 when quantitating the length of blood vessels in the tumors 
(I, Figure 4). TKI258 decreased migration of FGFR-amplified cells at 1 µM, and 
BGJ398 and AZD4547 at 100 nM concentrations in a wound healing assay (II, 
Figure 4). TKI258 decreased migration of MDA-MB-231(SA) cells at 5 µM 
concentration, and no effects were observed with FGFR-selective inhibitors. On the 
contrary, all inhibitors decreased invasion of MDA-MB-231(SA) cells at 5 µM 
concentration (II, Figure 4). 
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5.7 The effects of FGFR inhibitors on bone and 
osteoblast differentiation 
In the intratibial bone growth model, TKI258 decreased cancer-induced bone lesions 
evaluated by X-ray imaging (III, Figure 2). Correspondingly, total BMC and cortical 
BMC and BMD were higher in the tumor-bearing tibia in TKI258 treated mice 
compared to mice treated with vehicle (III, Figure 2). Additionally, the systemic 
level of osteoclasts was lower and bone formation was higher, as evaluated by 
TRACP 5b and PINP measurements in serum samples, respectively (III, Figure 2). 
No effects on osteoclast or osteoblast numbers were observed in healthy bone surface 
evaluated by histology (III, Supplement I).  
FGFRs are expressed in MSCs and their expression is changed during the 
differentiation to osteoblasts (IV, Figure 2). Expression of FGFR2 and FGFRL1 is 
increased during osteoblast differentiation, and silencing their expression inhibits the 
differentiation (IV, Figure 3 and Figure 4). This indicates that FGFR2 and FGFRL1 
are needed for MSC differentiation to osteoblasts. However, treatment of MSCs, pre-
osteoblasts, or mature osteoblasts in vitro with PD173073 at different stages of 
differentiation, or continuously during the differentiation process, had no effects on 
the differentiation when evaluated by expression of osteoblast marker genes (IV, 
Figure 3). 
5.8 Conclusions 
The results of this thesis study demonstrate that mRNA expression of FGFRs is 
increased in many breast cancer cell lines and also in breast cancer tissue samples 
obtained from patients. FGFR1 is a major regulator of breast cancer growth in S115 
cells in vitro and in vivo, whereas FGFR2 may mediate growth opposing signals in 
breast cancer cells. FGFR-amplified cells were about 50 times more sensitive to 
FGFR inhibition than non-FGFR amplified cells, and non-FGFR amplified cells 
responded differentially to FGFR inhibition. 
FGFR-amplified cells are most sensitive to FGFR-selective inhibitors BGJ398 
and AZD4547 compared to the non-selective FGFR inhibitor TKI258. FGFR-
amplified cells seemed to be more sensitive to FGFR inhibition in organoid cultures 
compared to traditional monolayer cultures. The preliminary results obtained from 
breast cancer explant cultures are in line with the findings from the other assays. 
FGFR inhibitors do not induce major apoptosis, and growth regulation of the 
inhibitors comes mainly through decreased proliferation. No effects on angiogenesis 
were observed with the FGFR inhibitors used, and the FGFR inhibitors had 
differential effects on migration and invasion of breast cancer cells. FGFR inhibitors 
decreased tumor growth and tumor-induced effects on bone. No adverse effects were 
observed on bone cells. 
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As a summary, the main effect of FGFR inhibitors was to decrease proliferation. 
This was observed in vitro and in vivo, and preliminarily verified with ex vivo explant 
cultures. Induction of apoptosis was only seen in organoid cultures, and some 
evidence of decreased migration and invasion was observed. No direct effects on 
bone cells were observed, which suggests that FGFRs inhibitors have no harmful 
effects on bone cells. The simplified key findings are summarized in Table 3 below.  
Table 3.  Summary of the FGFR inhibitors used in the study and simplified results of their effects 
on various parameters studied. “↓” = inhibition/decrease, “-“ = no effects, “NA” = data 
not available. 
 PD173074 TKI258 BGJ398 AZD4547 
Target 
IC50 (nM) 
FGFR1 25nM 
VEGFR 200nM 
FLT3 1nM 
c-Kit 2nM 
FGFR 1 8nM 
VEGFR 3 8nM 
FGFR 3 9nM 
FGFR1 0.9nM 
FGFR3 1.0nM 
FGFR2 1.4nM 
FGFR4 60nM 
FGFR1 0.2nM 
FGFR3 1.8nM 
FGFR2 2.5nM 
KDR 24nM 
FGFR signaling ↓ ↓ ↓ ↓ 
Proliferation in vitro 
(2D)  ↓ ↓ ↓ ↓ 
Proliferation in vitro 
(3D) NA ↓ ↓ ↓ 
Proliferation ex vivo NA ↓ ↓ ↓ 
Proliferation in vivo 
(s.c. model) ↓ NA NA NA 
Proliferation in vivo 
(i.t. model) NA ↓ NA NA 
Apoptosis in vitro 
(2D) NA - - - 
Apoptosis in vitro 
(3D) NA ↓ ↓ ↓ 
Apoptosis in vivo - NA NA NA 
Migration NA ↓ ↓ ↓ 
Invasion NA ↓ - - 
Bone cells in vitro - NA NA NA 
Bone in vivo  NA - NA NA 
 
 
 
 6 Discussion 
FGFRs or FGFR pathway is altered in about 18% of breast cancers (Helsten et al., 
2016). Currently, many FGFR inhibitors have ongoing clinical investigations in 
breast cancer patients with FGFR gene alterations. In this thesis we evaluated the 
role of FGFRs in breast cancer and studied the effects of four FGFR inhibitors in in 
vitro, in vivo and ex vivo breast cancer models.  
FGFR1 is the most commonly amplified FGFR receptor in breast cancer (Jain et 
al., 2012, Perez-Garcia et al., 2018) and in this thesis work, FGFR1 was observed to 
be the major regulator among FGFRs for promoting breast cancer cell growth, and 
increased proliferation and upregulation of Cyclin D1 was observed with increased 
expression of FGFR1. This has also been observed by others, and co-amplification 
of FGFR1 and CyclinD1 has been identified to decrease survival of breast cancer 
patients (Andre et al., 2015, Jain et al., 2012). Our results show that silencing of 
FGFR1 from mouse breast cancer cells strongly decreased proliferation. In the 
silencing experiments we also observed a regulation between FGFR1 and FGFR2. 
Silencing of FGFR2 increased the expression of FGFR1. To our knowledge, the 
mechanism of this regulation has not been clarified but it could be related for 
example to changes in the FGFR feedback system. However, this would suggest that 
low FGFR2 expression in tumors would be associated with increased expression of 
FGFR1. Thus, targeting FGFR2 could result in increased expression of FGFR1 and 
escape from FGFR2-targeted therapies, but this remains to be evaluated in future 
studies. A similar observation was made in breast tumors where increased expression 
of FGFR3 mediated the resistance to endocrine therapy (Tomlinson et al., 2012). 
Many breast cancer cell lines express FGFRs, but only a few of currently 
available cell lines have FGFR gene alterations (Turner et al., 2010). In this thesis 
work we used FGFR1 and FGFR2 amplified cell lines and two cell lines that do not 
have genetic alterations in FGFR genes. Our results show that FGFR amplified cells 
are about 50 times more sensitive to FGFR inhibition than non-amplified cells. 
However, cell lines without FGFR gene alterations can also respond to FGFR 
inhibition, but they need higher concentrations for inhibition of FGFR mediated 
signaling and proliferation. This is also observed in patients, as good responses for 
single agent FGFR inhibitors are typically observed in patients with high levels of 
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FGFR alterations. In general, patients have a moderate levels of FGFR 
amplifications, and a model with high level of amplified genes may not be predictive 
to a larger population of patients. Our results with non-FGFR amplified cell lines 
show that patients with no amplifications but FGFR driven or FGFR growth 
stimulated cancers may respond to FGFR inhibitor treatment, especially in 
combination with other therapies (Perez-Garcia et al., 2018). 
FGFR drug discovery has resulted in both FGFR selective and non-selective 
inhibitors. Due to a structural similarity of FGFRs to many other RTKs, many non-
selective FGFR inhibitors also target for example VEGFR. Targeting especially 
VEGFR is considered as an advantage, as dual-targeting of pathways responsible for 
angiogenesis could lead to better therapeutic efficacy. It is difficult to evaluate 
whether the FGFR selective or non-selective inhibitors have better efficacy, and 
most likely this will be case sensitive. Additionally, new FGFR targeting compounds 
such as second class reversible inhibitors have been developed (Farrell et al., 2018). 
In this thesis work we evaluated for the first time the effects of the non-selective 
FGFR inhibitors PD173074 and TKI258, and the selective FGFR inhibitors BGJ398 
and AZD4547 in breast cancer cells. When comparing the non-selective and 
selective FGFR inhibitors, the selective FGFR inhibitors BGJ398 and AZD4547 
were more effective in breast cancer cells but overall the inhibitors induced similar 
effects with same concentrations. 
The effects of TKI258, BGJ398 and AZD4547 on FGFR-mediated intracellular 
signaling in FGFR amplified and non-amplified breast cancer cells were studied in 
this thesis work. As expected, FGFR amplified cell lines were more sensitive to 
inhibition of FGFR-mediated signaling, and decreased proliferation was also 
observed at lower concentrations. In fact, the decrease in proliferation seemed to be 
the major cause of growth regression by the inhibitors. Only some signs of increased 
apoptosis were observed in 3D culture models, but not in traditional 2D monolayer 
cultures. The observed apoptosis in low nanomolar levels in the spheroids can be 
due to unspecific instead of FGFR-related effects. For example, a recent study 
showed that expression of certain kinases can determine the sensitivity to an FGFR 
inhibitor in an FGFR2 amplified gastric cancer model (Chen et al., 2019). The 
induction of apoptosis was the major difference observed in the results between 2D 
and 3D culture models in this study. Another difference was the sensitivity of the 
assays. All the cell lines were more sensitive to FGFR inhibition induced decrease 
to proliferation in 3D cultures compared to 2D culture conditions. This difference in 
sensitivity and expression of molecular markers has also been reported by others 
(Breslin et al., 2016, Imamura et al., 2015). In in vivo models, a trend towards 
increased apoptosis was observed. Others have reported increased apoptosis in vivo 
with PD173073 (Ye et al., 2014) and TKI258 (Dey et al., 2010). This thesis work 
showed that FGFR inhibitors have differential effects on migration and invasion of 
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breast cancer cells. Others have reported that PD173074 decreases both migration 
and invasion, which is supportive of the findings of this thesis work (Penault-Llorca 
et al., 1995). However, inhibition of migration and invasion is also reported for 
AZD4547, which is contradictory to our finding (Liu et al., 2014), but this could be 
due to differences in the assays used.  
Many cancer treatments induce adverse-effects in the skeleton (D'Oronzo et al., 
2015). This is also a concern for FGFR inhibitors, as FGFRs are widely expressed 
in and regulate many stromal cells, including bone cells (Katoh 2016, Ornitz et al., 
2015a), and FGFR germline mutations induce skeletal syndromes (Marie et al., 
2012). In this thesis work, no harmful bone effects were observed in mice treated 
with FGFR inhibitors, and also no effects were observed for the FGFR inhibitors on 
osteoblasts, suggesting that FGFR inhibitors do not have harmful effects on the 
skeleton at least in these experimental settings. However, a limitation of these 
experiments was the use of only one concentration of compounds that was sufficient 
to show the desired effects but did not allow to study potentially observable adverse 
effects at higher doses. Others have shown that FGFR inhibitors can decrease 
osteoclastogenesis and tumor-induces osteolysis similarly to our findings (Kang et 
al., 2019). 
Selecting the right patient population is important in clinical trials. A biomarker 
for determining FGFR status would help to evaluate clinical responses and to 
identify the optimal patient population that would benefit most from FGFR targeted 
therapies (Andre et al., 2015, De Luca et al., 2017). These approaches include for 
example PCR and in situ hybridization methods (Andre et al., 2013). This would 
also be important for predicting adverse effects of FGFR inhibitors. FGFR selective 
inhibitors usually have higher binding affinity to FGFRs and less adverse effects 
compared to non-selective inhibitors with wider range of kinase inhibition and off-
target toxicities. To study inhibitor effects and inhibitor engagement with the target, 
serum FGF23 and phosphate levels can be used as biomarkes of treatment response 
(Wu et al., 2013, Wöhler et al., 2013). 
Resistance is a problem with many, if not all targeted therapies (Criscitiello et 
al., 2015). FGFRs have been observed to mediate resistance to conventional 
therapies (Dieci et al., 2013), and also to HER2 and VEGF targeting therapies (Andre 
et al., 2015). In the case of HER2, the resistance could be overcome by dual treatment 
of FGFR and HER2 inhibition (Andre et al., 2015). FGFR4 expression increases for 
example in models that are resistant to chemotherapy, and the high expression of 
FGFR4 correlates with poor clinical benefit and shortened progression free survival 
(Andre et al., 2015). This demonstrates the importance of evaluating FGFR4 levels 
and developing new compounds that would also target FGFR4.  
In conclusion, we showed in this thesis that FGFRs are potential drug targets and 
regulators of growth and progression of breast cancer. Especially FGFR1 is an 
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important regulator of breast cancer growth, and targeting FGFRs with selective and 
non-selective FGFR inhibitors induced mainly decreased proliferation of breast 
cancer cells and tumors. Importantly, this thesis showed that FGFR inhibitors did 
not have unwanted effects in the skeleton, even though FGFR are important 
regulators in bone. Clinical trials currently evaluate FGFR inhibitors as single agents 
and in combination with several other therapies in breast cancer patients. There are 
some challenges also described in this thesis such as patient selection, development 
of resistance, and adverse effects that may hinder this development. However, FGFR 
drug development has been promising and the approval of the first FGFR targeting 
compound erdafitinib for advanced bladder cancer will hopefully fasten the 
development in breast cancer.
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